Document:

Exhibit 10.59

 

APOLLO
MEDICAL HOLDINGS, INC.

 

2015
EQUITY INCENTIVE PLAN

 

1.
Purpose, History and Effective Date.

 

(a)
Purpose.
The Apollo Medical Holdings, Inc. 2015 Equity Incentive Plan has two complementary purposes: (i) to attract and retain outstanding
individuals to serve as officers, employees, directors or consultants and (ii) to increase stockholder value. The Plan will provide
participants incentives to increase stockholder value by offering the opportunity to acquire shares of the Company's common stock
or receive monetary payments based on the value of such common stock on the potentially favorable terms that this Plan provides.

 

(b)
History.
Prior to the effective date of this Plan, the Company had in effect the 2010 Plan and the 2013 Plan, which were originally effective
March 4, 2010 and April 30, 2013, respectively. Upon adoption of this Plan by the Board, no new awards will be granted under the
2013 Plan. No awards have been granted under the 2010 Plan since the effectiveness of the 2013 Plan.

 

(c)
Effective Date.
This Plan will become effective, and Awards may be granted under this Plan, on and after the Effective Date; provided, however,
that prior to approval of this Plan by the Company's stockholders, but after adoption by the Board, Incentive Stock Options may
be granted under this Plan subject to obtaining the stockholders' approval of this Plan; and provided, further, that such stockholder
approval must occur no later than 12 months after the date of adoption of this Plan by the Board. This Plan will terminate as provided
in Section 14.

 

2.
Definitions.
Capitalized terms used in this Plan have the following meanings:

 

(a)
"2010" Plan means the Apollo Medical Holdings, Inc. 2010 Equity Incentive Plan.

 

(b)
"2013 Plan" means the Apollo Medical Holdings, Inc. 2013 Equity Incentive Plan.

 

(c)
"Affiliate" has the meaning ascribed to such term in Rule 12b-2 promulgated under
the Exchange Act or any successor rule or regulation thereto.

 

(d)
"Award" means a grant of Options, Stock Appreciation Rights, Performance Shares,
Performance Units, Restricted Stock, Restricted Stock Units or Dividend Equivalent Units.

 

(e)
"Award Agreement" means a written agreement, contract, or other instrument or document
evidencing the grant of an Award in such form as the Committee determines.

 

(f)
"Board" means the Board of Directors of the Company.

 

    	 	1	 

     

    

  

(g)
"Change of Control" means the occurrence of any one of the following events:

 

(i)
the consummation of a merger or consolidation of the Company with or into another entity
or any other corporate reorganization, if more than fifty percent (50%) of the combined voting power of the continuing or surviving
entity's securities outstanding immediately after such merger, consolidation or other reorganization is owned by Persons who were
not stockholders of the Company immediately prior to such merger, consolidation or other reorganization;

 

(ii)
 the sale, transfer or other disposition of all or substantially all of the Company's assets;

 

(iii)
a change in the composition of the Board, as a result of which fewer than fifty percent (50%)
of the incumbent directors are directors who either (A) had been directors of the Company on the date twenty-four (24) months prior
to the date of the event that may constitute a Change of Control (the "original directors") or (B) were elected, or nominated
for election, to the Board with the affirmative votes of at least a majority of the aggregate of the original directors who were
still in office at the time of the election or nomination and the directors whose election or nomination was previously so approved;
or

 

(iv)
any transaction as a result of which any Person is the "beneficial owner" (as defined
in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing at least fifty percent
(50%) of the total voting power represented by the Company's then outstanding voting securities. For purposes of this paragraph
(iv), the term "Person" shall exclude (A) a trustee or other fiduciary holding securities under an employee benefit plan
of the Company or a Subsidiary and (B) a corporation owned directly or indirectly by the stockholders of the Company in substantially
the same proportions as their ownership of the common stock of the Company.

 

A
transaction shall not constitute a Change of Control if its sole purpose is to change the state of the Company's incorporation
or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities
immediately before such transaction.

 

Notwithstanding
anything herein contained to the contrary, with respect to an Award that is or may be considered deferred compensation subject
to Code Section 409A, the definition of "Change of Control" herein shall be amended and interpreted in a manner that
allows the definition to satisfy the requirements of a change of control under Code Section 409A solely for purposes of complying
with the requirements of Code Section 409A.

 

    	 	2	 

     

    

 

(h)
"Code" means the Internal Revenue Code of 1986, as amended. Any reference to a
specific provision of the Code includes any successor provision and the regulations promulgated under such provision.

 

(i)
"Committee" means the Compensation Committee of the Board (or a successor committee
with the same or similar authority), except as otherwise provided in Section 3(b).

 

(j)
"Company" means Apollo Medical Holdings, Inc., a Delaware corporation, or any successor thereto.

 

(k)
"Director" means a member of the Board, and "Non-Employee Director" means a Director who is not also an employee
of the Company or its Subsidiaries.

 

(l)
"Disability" has the meaning ascribed to the term in Code Section 22(e)(3), as determined by the Committee.

 

(m)
"Disinterested Persons" means the "non-employee directors" of the Company as such term is defined in Rule 16b-3.

 

(n)
"Dividend Equivalent Unit" means the right to receive a payment equal to the cash dividends paid with respect to a Share.

 

(o)
"Effective Date" means the earlier to occur of the date this Plan is (i) adopted by the Board or (ii) approved by the
Company's stockholders.

 

(p)
"Exchange Act" means the Securities Exchange Act of 1934, as amended. Any reference to a specific provision of the Exchange
Act includes any successor provision and the regulations and rules promulgated under such provision.

 

(q)
"Fair Market Value" means, per Share on a particular date, (i) if the Stock is listed for trading on the New York Stock
Exchange, the last reported sales price on the date in question as reported in The Wall Street Journal, or if no sales of Stock
occur on the date in question, on the last preceding date on which there was a sale on such exchange; or (ii) if the Stock is not
listed or admitted to trading on the New York Stock Exchange, the last reported sales price on the date in question on the principal
national securities exchange on which the Stock is listed or admitted to trading, or if no sales of Stock occur on the date in
question, on the last preceding date on which there was a sale on such exchange; or (iii) if the Stock is not listed or admitted
to trading on any national securities exchange, the last sales price on the date in question in the over-the-counter market reported
by such reporting system as is then in use, or if no sales of Stock occur on the date in question, on the last preceding date on
which there was a sale; or (iv) if on any such date the Stock is not reported on any such system, the last sales price on the date
in question as furnished by a professional market making a market in the Stock selected by the Board for the date in question,
or if no sales of Stock occur on the date in question, on the last preceding date on which there was a sale; or (v) if on any such
date no market maker is making a market in the Stock, the price as determined in good faith by the Committee.

 

    	 	3	 

     

    

  

(r)
"Incentive Stock Option" means an Option that meets the requirements of Code Section 422.

 

(s)
"Option" means the right to purchase Shares at a specified price during a specified period of time.

 

(t)
"Participant" means an individual selected by the Committee to receive an Award, and includes any individual who holds
an Award after the death of the original recipient.

 

(u)
"Performance Goals" means any goals the Committee establishes that relate to one or more of the following for such period
as the Committee specifies:

 

(i)
Revenue;

 

(ii)
 Earnings before interest, taxes, depreciation and amortization, as adjusted
(EBITDA as adjusted);

 

(iii)
Income before income taxes and minority interests;

 

(iv)
Operating income;

 

(v)
 Pre- or after-tax income;

 

(vi)
Average accounts receivable;

 

(vii)
 Cash flow;

 

(viii)
Cash flow per share;

 

(ix)
 Net earnings;

 

(x)
Basic or diluted earnings per share;

 

(xi)
 Return on equity;

 

(xii)
Return on assets;

 

(xiii)
 Return on capital;

 

(xiv)
Growth in assets;

 

(xv)
 Economic value added;

 

(xvi)
Share price performance;

 

    	 	4	 

     

    

 

(xvii)
 Total stockholder return;

 

(xviii)
Improvement or attainment of expense levels;

 

(xix)
 Market share or market penetration; or

 

(xx)
Business expansion, and/or acquisitions or divestitures.

 

The
Committee may specify at the time an Award is made that the Performance Goals are to be measured for an individual, the Company,
for the Company on a consolidated basis, for any one or more Affiliates or divisions of the Company and/or for any other business
unit or units of the Company, and/or that the Performance Goals are to be measured either in absolute terms or relative to the
performance of one or more comparable companies or an index covering multiple companies. In the case of Awards that the Committee
determines will not be considered "performance based compensation" under Code Section 162(m), the Committee may establish
other Performance Goals not listed in this Plan.

 

(v)
"Performance Shares" means the right to receive Shares to the extent Performance Goals are achieved.

 

(w)
"Performance Units" means the right to receive a payment, based on a number of units with a specified value, to the extent
Performance Goals are achieved.

 

(x)
"Person" has the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 14(d) and 15(d)
thereof.

 

(y)
"Plan" means this Apollo Medical Holdings, Inc. 2015 Equity Incentive Plan, as may be amended from time to time.

 

(z)
"Restricted Stock" means Shares that are subject to a risk of forfeiture and/or restrictions on transfer, which may lapse
upon the achievement or partial achievement of Performance Goals and/or upon the completion of a period of service.

 

(aa)
"Restricted Stock Unit" means the right to receive a payment which right may vest upon the achievement or partial achievement
of Performance Goals and/or upon the completion of a period of service, with each unit having a value equal to the Fair Market
Value of one or more Shares, or the average of the Fair Market Value of one or more Shares over such period as the Committee specifies.

 

(bb)
"Retirement" means, unless the Committee determines otherwise in an Award Agreement, termination of employment from the
Company and its Affiliates on or after age 65 with five (5) years of continuous service with the Company and its Affiliates.

 

(cc)
"Rule 16b-3" means Rule 16b-3 as promulgated by the United States Securities and Exchange Commission under the Exchange
Act.

 

    	 	5	 

     

    

  

(dd)
"Section 16 Participants" means Participants who are subject to the provisions of Section 16 of the Exchange Act.

 

(ee)
"Share" means a share of Stock.

 

(ff)
"Stock" means the Class A common stock of the Company.

 

(gg)
"Stock Appreciation Right" or "SAR" means the right to receive a payment equal to the appreciation of the Fair
Market Value of a Share during a specified period of time.

 

(hh)
"Subsidiary" means any corporation (other than the Company) in an unbroken chain of corporations beginning with the Company
if each such corporation owns stock possessing fifty percent (50%) or more of the total combined voting power in one of the other
corporations in the chain.

 

3.
Administration.

 

(a)
Committee Administration.
In addition to the authority specifically granted to the Committee in this Plan, the Committee has full discretionary authority
to administer this Plan, including but not limited to the authority to (i) interpret the provisions of this Plan, (ii) prescribe,
amend and rescind rules and regulations relating to this Plan, (iii) correct any defect, supply any omission, or reconcile any
inconsistency in the Plan, any Award or Award Agreement in the manner and to the extent it deems desirable to carry this Plan,
such Award or such Award Agreement into effect and (iv) make all other determinations necessary or advisable for the administration
of this Plan. All decisions, interpretations and other actions of the Committee shall be final and binding on all Participants
and any other individual with a right under the Plan or under any Award.

 

(b)
Delegation to Other Committees or CEO.
To the extent applicable law permits, the Board may delegate to another committee of the Board, or the Committee may delegate to
a subcommittee or to the Chief Executive Officer of the Company, any or all of the authority and responsibility of the Committee;
provided, however, that no such delegation shall be permitted with respect to Awards made to Section 16 Participants. The Board
may retain any or all of the authority and responsibility of the Committee, or may delegate to another committee or subcommittee
of the Board consisting solely of two or more Disinterested Persons any or all of the authority and responsibility of the Committee,
with respect to Section 16 Participants. If the Board or Committee has retained such authority or made such a delegation, then
all references to the Committee in this Plan include the Board, such other committee, subcommittee or the Chief Executive Officer
to the extent of such retained authority or delegation.

 

    	 	6	 

     

    

  

(c)
Indemnification.
In addition to such other rights of indemnification as they may have as members of the Board or the Committee, the members of the
Board and the Committee shall be indemnified by the Company against all costs and expenses reasonably incurred by them in connection
with any action, suit or proceeding to which they or any of them may be party by reason of any action taken or failure to act under
or in connection with the Plan or any Award, and against all amounts paid by them in settlement thereof (provided such settlement
is approved by independent legal counsel selected by the Company) or paid by them in satisfaction of a judgment in any such action,
suit or proceeding, except a judgment based upon a finding of bad faith; provided that upon the institution of any such action,
suit or proceeding a Committee or Board member shall, in writing, give the Company notice thereof and an opportunity, at its own
expense, to handle and defend the same before such Committee or Board member undertakes to handle and defend it on such member's
own behalf.

 

4.
Eligibility.
The Committee may designate any of the following as a Participant from time to time: (i) any officer or other employee of the Company
or any of its Affiliates; (ii) an individual that the Company or an Affiliate has engaged to become an officer or other employee;
(iii) a Non-Employee Director' or (iv) a consultant or advisor who provides bona fide services that are not in connection with
the offer or sale of securities in a capital raising transaction, and does not directly or indirectly promote or maintain a market
for the Company's securities to the Company or an Affiliate as an independent contractor. The Committee's designation of a Participant
in any year will not require the Committee to designate such person to receive an Award in any other year. Notwithstanding the
foregoing, each Non-Employee Director automatically will be a Participant with respect to elections to receive Options in lieu
of directors' fees pursuant to Section 12.

 

5.
Types of Awards.
Subject to the terms of this Plan, the Committee may grant any type of Award to any Participant it selects, but only employees
of the Company or a Subsidiary may receive grants of Incentive Stock Options. Awards may be granted alone or in addition to, in
tandem with, or in substitution for any other Award (or any other award granted under another plan of the Company or any Affiliate).
Awards granted under the Plan shall be evidenced by an Award Agreement except to the extent the Committee provides otherwise.

 

6.
Shares Reserved under this Plan.

 

(a)
Plan Reserve.
Subject to adjustment as provided in Section 16, an aggregate of 1,500,000 Shares, plus the number of Shares described in Section
6(c), are reserved for issuance under this Plan. The number of Shares reserved for issuance under this Plan shall be reduced only
by the number of Shares delivered in payment or settlement of Awards. Notwithstanding the foregoing, the Company may issue only
1,500,000 Shares upon the exercise of Incentive Stock Options.

 

(b)
Replenishment of Shares Under this Plan.
If an Award lapses, expires, terminates or is cancelled without the issuance of Shares under the Award, or if Shares are forfeited
under an Award, then the Shares subject to such Award may again be used for new Awards under this Plan under Section 6(a), including
issuance upon the exercise of Incentive Stock Options. If Shares are issued under any Award and the Company subsequently reacquires
them pursuant to rights reserved upon the issuance of the Shares, or if previously owned Shares are delivered to the Company in
payment of the exercise price of an Award or the withholding taxes due as a result of the issuance or receipt of a payment or Shares
under an Award, then such Shares may again be used for new Awards under this Plan under Section 6(a), but such Shares may not be
issued upon the exercise of Incentive Stock Options.

 

    	 	7	 

     

    

  

(c)
Addition of Shares from Predecessor Plan.
After the Effective Date, if any Shares subject to awards granted under the 2010 Plan or 2013 Plan would again become available
for new grants under the terms of such plan, then those Shares will be available for the purpose of granting Awards under this
Plan, thereby increasing the number of Shares available for issuance under this Plan as determined under the first sentence of
Section 6(a), including with respect to the exercise of Incentive Stock Options. Any such Shares will not be available for future
awards under the respective terms of the 2010 Plan and 2013 Plan after the Effective Date.

 

(d)
Participant Limitations.
Subject to adjustment as provided in Section 16, with respect to Awards that are intended to qualify as "performance-based
compensation" under Code Section 162(m), no Participant may be granted Awards that could result in such Participant:

 

(i)
receiving in any calendar year Options for, and/or Stock Appreciation Rights with respect
to, more than 500,000 Shares (reduced, in the initial calendar year in which this Plan is effective, by the number of options granted
to a Participant under the 2010 Plan and/or 2013 Plan in such year, if any), except that Options and/or Stock Appreciation Rights
granted to a new employee in the calendar year in which his or her employment commences may not relate to more than 1,000,000 Shares;

 

(ii)
 receiving in any calendar year Awards of Restricted Stock and/or Restricted Stock Units
relating to more than 500,000 Shares;

 

(iii)
receiving in any calendar year Awards of Performance Shares, and/or Awards of Performance
Units (the value of which is based on the Fair Market Value of a Share), for more than 500,000 Shares; or

 

(iv)
receiving in any calendar year Awards of Performance Units (the value of which is not based
on the Fair Market Value of a Share) that could result in a payment of more than $500,000.

 

With
respect to Awards that are not intended to meet the requirements of performance- based compensation under Code Section 162(m),
the Committee may grant Awards in excess of the limits described in this subsection (d), but only if such discretion would not
cause Awards that are intended to be performance-based compensation under Code Section 162(m) from being treated as such.

 

    	 	8	 

     

    

  

7.
Options. Subject to the terms of this Plan, the Committee
shall determine all terms and conditions of each Option, including but not limited to:

 

(a)
Whether the Option is an Incentive Stock Option, or a "nonqualified stock option"
which does not meet the requirements of Code Section 422; provided that in the case of an Incentive Stock Option, if the aggregate
Fair Market Value (determined at the time of grant) of the Shares with respect to which all Incentive Stock Options are first exercisable
by the Participant during any calendar year (under this Plan and under all other incentive stock option plans of the Company or
any Affiliate that is required to be included under Code Section 422) exceeds $100,000, such Option automatically shall be treated
as a nonqualified stock option to the extent this limit is exceeded.

 

(b)
The number of Shares subject to the Option.

 

(c)
The exercise price per Share, which may not be less than the Fair Market Value of a Share
as determined on the date of grant; provided that (i) no Incentive Stock Option shall be granted to any employee who, at the time
the Option is granted, owns (directly or indirectly, within the meaning of Code Section 424(d)) more than ten percent of the total
combined voting power of all classes of stock of the Company or of any Subsidiary unless the exercise price is at least 110 percent
of the Fair Market Value of a Share on the date of grant; and (ii) the exercise price may vary during the term of the Option if
the Committee determines that there should be adjustments to the exercise price relating to achievement of Performance Goals and/or
to changes in an index or indices that the Committee determines is appropriate (but in no event may the exercise price per Share
be less than the Fair Market Value of a Share as determined on the date of grant).

 

(d)
The terms and conditions of exercise, which may include a requirement that exercise of the
Option is conditioned upon achievement of one or more Performance Goals or may provide for an acceleration of the exercisability
upon the Participant's death, Disability or Retirement.

 

(e)
The termination date, except that each Option must terminate no later than the tenth (10th)
anniversary of the date of grant, and each Incentive Stock Option granted to any employee who, at the time the Option is granted,
owns (directly or indirectly, within the meaning of Code Section 424(d)) more than ten percent (10%) of the total combined voting
power of all classes of stock of the Company or of any Subsidiary must terminate no later than the fifth (5th) anniversary of the
date of grant. Notwithstanding the foregoing, the Committee may extend the term of an Option for up to six (6) months beyond the
tenth (10th) anniversary of the date of grant in the event a Participant dies prior to the Option's termination date.

 

(f)
The exercise period following a Participant's termination of employment or service. In all
other respects, the terms of any Incentive Stock Option should comply with the provisions of Code Section 422 except to the extent
the Committee determines otherwise.

 

    	 	9	 

     

    

  

(g)
Notwithstanding anything contained in this Plan to the contrary, the Board as a whole shall pre-approve each option grant to Non-Employee
Directors.

 

8.
Stock Appreciation Rights.
Subject to the terms of this Plan, the Committee shall determine all terms and conditions of each SAR, including but not limited
to:

 

(a)
Whether the SAR is granted independently of an Option or relates to an Option; provided that
if an SAR is granted in relation to an Option, then unless otherwise determined by the Committee, the SAR shall be exercisable
or shall mature at the same time or times, on the same conditions and to the extent and in the proportion, that the related Option
is exercisable and may be exercised or mature for all or part of the Shares subject to the related Option. Upon exercise of any
number of SARs, the number of Shares subject to the related Option shall be reduced accordingly and such Option may not be exercised
with respect to that number of Shares. The exercise of any number of Options that relate to an SAR shall likewise result in an
equivalent reduction in the number of Shares covered by the related SAR.

 

(b)
The number of Shares to which the SAR relates.

 

(c)
The grant price, provided that the grant price shall not be less than the Fair Market Value
of the Shares subject to the SAR as determined on the date of grant.

 

(d)
The terms and conditions of exercise or maturity, which may include a provision that accelerates
the exercisability of the SAR upon the Participant's death, Disability or Retirement. Notwithstanding the foregoing, unless the
Committee determines otherwise in the Award Agreement, if on the date when the SAR expires or otherwise terminates, the grant price
for the SAR is less than the Fair Market Value of a Share, then the unexercised portion of the SAR that was exercisable immediately
prior to such date shall automatically be deemed exercised.

 

(e)
The term, provided that an SAR must terminate no later than 10 years after the date of grant.
Notwithstanding the foregoing, the Committee may extend the term of an SAR for up to six (6) months beyond the tenth (10th) anniversary
of the date of grant in the event a Participant dies prior to the SAR's termination date.

 

(f)
Whether the SAR will be settled in cash, Shares or a combination thereof.

 

(g)
Notwithstanding anything contained in this Plan to the contrary, the Board as a whole shall
pre-approve each SAR grant to Non-Employee Directors.

 

9.
Performance Awards.
Subject to the terms of this Plan, the Committee shall determine all terms and conditions of each award of Performance Shares or
Performance Units, including but not limited to:

 

(a)
The number of Shares and/or units to which such Award relates, and with respect to Performance Units, whether the value of each
unit will be based on the Fair Market Value of one or more Shares, the average of the Fair Market Value of one or more Shares over
such period as the Committee specifies, or such other value as the Committee specifies in the Award Agreement.

 

    	 	10	 

     

    

  

(b)
One or more Performance Goals that must be achieved during such period as the Committee specifies
in order for the Participant to realize the benefit of such Award.

 

(c)
Whether all or a portion of the Performance Goals subject to an Award are deemed achieved
upon a Participant's death, Disability or Retirement.

 

(d)
With respect to Performance Units, whether to settle such Award in cash, Shares, or a combination
of cash and Shares.

 

(e)
Notwithstanding anything contained in this Plan to the contrary, the Board as a whole shall
pre-approve each Award grant under this Section 9 to Non-Employee Directors.

 

Unless
otherwise provided by the Committee, a Participant shall not be entitled to and shall agree to waive or otherwise surrender any
rights to receive dividends or dividend equivalents paid with respect to Performance Shares or Performance Units valued in Shares
until after the Performance Shares or Performance Units have been earned.

 

10.
Restricted Stock and Restricted Stock Unit Awards.

 

Subject
to the terms of this Plan, the Committee shall determine all terms and conditions of each award of Restricted Stock or Restricted
Stock Units, including but not limited to:

 

(a)
The number of Shares and/or units to which such Award relates.

 

(b)
The period of time over which the restrictions imposed on Restricted Stock will lapse and
the vesting of Restricted Stock Units will occur, and whether, as a condition for the Participant to realize all or a portion of
the benefit provided under the Award, one or more Performance Goals must be achieved during such period as the Committee specifies;
provided that, subject to the provisions of Section 10(c), an Award that is subject to the achievement of Performance Goals must
have a restriction or vesting period of at least one year, and an Award that is not subject to Performance Goals must have a restriction
or vesting period of at least three years. Notwithstanding the foregoing, if the Committee determines in its sole discretion that
an Award of Restricted Stock or Restricted Stock Units is granted to a Participant in lieu of cash compensation (including without
limitation bonus cash compensation), the Committee may impose such restriction or vesting period on such Award as it determines.

 

(c)
Whether all or any portion of the restrictions or vesting schedule imposed on the Award will
lapse or be accelerated upon a Participant's death, Disability or Retirement.

 

(d)
With respect to Restricted Stock Units, whether to settle such Awards in cash, Shares, or
a combination of cash and Shares.

 

    	 	11	 

     

    

  

(e)
With respect to Restricted Stock, the manner of registration of certificates for such Shares,
and whether to hold such Shares in escrow pending lapse of the restrictions or to issue such Shares with an appropriate legend
referring to such restrictions.

 

(f)
Whether dividends paid with respect to an Award of Restricted Stock will be immediately paid
or held in escrow or otherwise deferred and whether such dividends shall be subject to the same terms and conditions as the Award
to which they relate.

 

(g)
Notwithstanding anything contained in this Plan to the contrary, the Board as a whole shall
pre-approve each grant under this Section 10 to Non-Employee Directors.

 

11.
 Dividend Equivalent Units.
Subject to the terms and conditions of this Plan, the Committee shall determine all terms and conditions of each award of Dividend
Equivalent Units, including but not limited to whether such Award will be granted in tandem with another Award, and the form, timing
and conditions of payment.

 

12.
 Payment of Directors' Fees in Options.
Subject to such restrictions as may be imposed by the Board, a Non-Employee Director may elect to receive all or any portion of
his or her annual cash retainer payment from the Company in the form of Options. The number of Options granted as a result of such
election shall be determined by multiplying the amount of foregone cash compensation by four (4), and dividing such product by
the Fair Market Value of a Share on the date the cash compensation would have otherwise been paid to the Non-Employee Director.

Such
Options shall be issued under and subject to the terms of this Plan. An election under this Section 12 shall be filed with the
Company on such form and in such manner as the Board determines. The Board as a whole shall pre-approve each option grant under
this Section 12.

 

13.
 Transferability.
Awards are not transferable other than by will or the laws of descent and distribution, unless and to the extent the Committee
allows a Participant to: (a) designate in writing a beneficiary to exercise the Award after the Participant's death; or (b) transfer
an Award.

 

14.
 Termination and Amendment of Plan; Amendment,
Modification or Cancellation of Awards.

 

(a)
Term of Plan.
This Plan will terminate on the tenth anniversary of the Effective Date unless the Board or Committee earlier terminates this Plan
pursuant to Section 14(b).

 

(b)
Termination and Amendment.
The Board or the Committee may amend, suspend or terminate this Plan at any time, subject to the following limitations:

 

(i)
the Board must approve any amendment, suspension or termination of this Plan to the extent the Company determines such approval
is required by: (A) action of the Board, (B) applicable corporate law, (C) the listing requirements of any principal securities
exchange or market on which the Shares are then traded, or (D) any other applicable law;

 

    	 	12	 

     

    

  

(ii)
 stockholders must approve any amendment of this Plan to the extent the Company determines
such approval is required by: (A) Section 16 of the Exchange Act, (B) the Code, (C) the listing requirements of any principal securities
exchange or market on which the Shares are then traded, or (D) any other applicable law; and

 

(iii)
stockholders must approve any of the following Plan amendments: (A) an amendment to materially
increase any number of Shares specified in Section 6(a) or 6(d) (except as permitted by Section 16); or (B) an amendment to the
provisions of Section 14(e).

 

(c)
Amendment, Modification or Cancellation of
Awards. Except as provided in Section 14(e) and subject to the requirements of
this Plan, the Committee may modify or amend any Award or waive any restrictions or conditions applicable to any Award or the exercise
of the Award, and the terms and conditions applicable to any Awards may at any time be amended, modified or canceled by mutual
agreement between the Committee and the Participant, so long as any amendment or modification does not increase the number of Shares
issuable under this Plan (except as permitted by Section 16), but the Committee need not obtain Participant (or other interested
party) consent for the cancellation of an Award pursuant to the provisions of Section 16(a) or the modification of an Award to
the extent deemed necessary to comply with any applicable law or the listing requirements of any principal securities exchange
or market on which the Shares are then traded, or to preserve favorable accounting treatment of any Award for the Company.

 

(d)
Survival of Authority and Awards.
Notwithstanding the foregoing, the authority of the Board and the Committee under this Section 14 will extend beyond the date of
this Plan's termination. In addition, termination of this Plan will not affect the rights of Participants with respect to Awards
previously granted to them, and all unexpired Awards will continue in force and effect after termination of this Plan except as
they may lapse or be terminated by their own terms and conditions.

 

(e)
Repricing and Backdating Prohibited.
Notwithstanding anything in this Plan to the contrary, and except for the adjustments provided in Section 16, neither the Committee
nor any other person may decrease the exercise or grant price for any outstanding Option or SAR after the date of grant, cancel
an outstanding Option or SAR in exchange for cash or other Awards (other than cash or other Awards with a value equal to the excess
of the Fair Market Value of the Shares subject to such Option or SAR at the time of cancellation over the exercise or grant price
for such Shares) or allow a Participant to surrender an outstanding Option or SAR to the Company as consideration for the grant
of a new Option or SAR with a lower exercise price. In addition, the Committee may not make a grant of an Option or SAR with a
grant date that is effective prior to the date the Committee takes action to approve such Award.

 

    	 	13	 

     

    

  

(f)
Foreign Participation.
To assure the viability of Awards granted to Participants employed in foreign countries, the Committee may provide for such special
terms as it may consider necessary or appropriate to accommodate differences in local law, tax policy or custom. Moreover, the
Committee may approve such supplements to, or amendments, restatements or alternative versions of, this Plan as it determines is
necessary or appropriate for such purposes. Any such amendment, restatement or alternative versions that the Committee approves
for purposes of using this Plan in a foreign country will not affect the terms of this Plan for any other country. In addition,
all such supplements, amendments, restatements or alternative versions must comply with the provisions of Section 14(b)(ii).

 

(g)
Recoupment.
Any Awards granted pursuant to the Plan, and any Stock issued or cash paid pursuant to an Award, shall be subject to (A) any recoupment,
clawback, equity holding, stock ownership or similar policies adopted by the Company from time to time and (B) any recoupment,
clawback, equity holding, stock ownership or similar requirements made applicable by law, regulation or listing standards to the
Company from time to time.

 

15.
Taxes.

 

(a)
Withholding Right.
The Company is entitled to withhold the amount of any tax attributable to any amount payable or Shares deliverable under this Plan
after giving the person entitled to receive such amount or Shares notice as far in advance as practicable, and the Company may
defer making payment or delivery if any such tax may be pending unless and until indemnified to its satisfaction.

 

(b)
Use of Shares to Satisfy Tax Withholding.
A Participant shall have the right to satisfy all or a portion of the federal, state and local withholding tax obligations arising
in connection with an Award by electing to (i) have the Company withhold Shares otherwise issuable under the Award, (ii) tender
back Shares received in connection with such Award or (iii) deliver other previously owned Shares, in each case having a Fair Market
Value equal to the amount to be withheld. However, the amount to be withheld may not exceed the total minimum federal, state and
local tax withholding obligations associated with the transaction to the extent required to avoid an expense on the Company's financial
statements. The election must be made on or before the date as of which the amount of tax to be withheld is determined and otherwise
as the Committee requires.

 

(c)
No Guarantee of Tax Treatment.
Notwithstanding any provision of the Plan to the contrary, the Company does not guarantee to any Participant or any other person
with an interest in an Award that (i) any Award intended to be exempt from Code Section 409A shall be so exempt, (ii) any Award
intended to comply with Code Section 409A or Code Section 422 shall so comply, or (iii) any Award shall otherwise receive a specific
tax treatment under any other applicable tax law, nor in any such case will the Company or any Affiliate be obligated to indemnify,
defend or hold harmless any individual with respect to the tax consequences of any Award.

 

    	 	14	 

     

    

 

(d)
Participant Responsibility. If a Participant shall dispose
of Stock acquired through exercise of an Incentive Stock Option within either (i) two years after the date the Option is granted
or (ii) one year after the date the Option is exercised (i.e., in a disqualifying disposition), such Participant shall notify the
Company within seven days of the date of such disqualifying disposition.

 

16.
Adjustment Provisions; Change of Control.

 

(a)
Adjustment of Shares. If the Committee determines that any
dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock
split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of
Shares or other securities of the Company, issuance of warrants or other rights to purchase Shares or other securities of the Company,
or other similar corporate transaction or event affects the Shares such that the Committee determines an adjustment to be appropriate
to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under this Plan, then, subject
to Participants' rights under Section 16(c), the Committee shall, in such manner as it may deem equitable, adjust any or all of
(i) the number and type of Shares subject to this Plan (including the number and type of Shares described in Sections 6(a) and
6(d)), and which may after the event be made the subject of Awards under this Plan, (ii) the number and type of Shares subject
to outstanding Awards, and (iii) the grant, purchase, or exercise price with respect to any Award. In any such case, the Committee
may also (or in lieu of the foregoing) make provision for a cash payment to the holder of an outstanding Award in exchange for
the cancellation of all or a portion of the Award (without the consent of the holder of an Award) in an amount determined by the
Committee effective at such time as the Committee specifies (which may be the time such transaction or event is effective), but
if such transaction or event constitutes a Change of Control, then (A) such payment shall be at least as favorable to the holder
as the amount the holder could have received in respect of such Award under Section 16(c) and (b) from and after the Change of
Control, the Committee may make such a provision only if the Committee determines that doing so is necessary to substitute, for
each Share then subject to an Award, the number and kind of shares of stock, other securities, cash or other property to which
holders of Stock are or will be entitled in respect of each Share pursuant to the transaction or event in accordance with the last
sentence of this subsection (a). However, in each case, with respect to Awards of Incentive Stock Options, no such adjustment may
be authorized to the extent that such authority would cause this Plan to violate Code Section 422(b). Further, the number of Shares
subject to any Award payable or denominated in Shares must always be a whole number. Without limitation, subject to Participants'
rights under Section 16(c), in the event of any reorganization, merger, consolidation, combination or other similar corporate transaction
or event, whether or not constituting a Change of Control (other than any such transaction in which the Company is the continuing
corporation and in which the outstanding Stock is not being converted into or exchanged for different securities, cash or other
property, or any combination thereof), the Committee may substitute, on an equitable basis as the Committee determines, for each
Share then subject to an Award, the number and kind of shares of stock, other securities, cash or other property to which holders
of Stock are or will be entitled in respect of each Share pursuant to the transaction.

 

    	 	15	 

     

    

  

(b)
Issuance or Assumption.
Notwithstanding any other provision of this Plan, and without affecting the number of Shares otherwise reserved or available under
this Plan, in connection with any merger, consolidation, acquisition of property or stock, or reorganization, the Committee may
authorize the issuance of substitute awards or assumption of awards under this Plan by another party to any such merger, consolidation,
acquisition or reorganization upon such terms and conditions as it may deem appropriate.

 

(c)
Change of Control.

 

(i)
The Committee may specify, either in an Award Agreement or at the time of a Change of Control,
whether an outstanding Award shall become vested and/or payable, in whole or in part, as a result of a Change of Control.

 

(ii)
 If, in connection with the Change of Control, the Options and SARs issued under the
Plan are not assumed, or if substitute Options and SARs are not issued by the successor or Affiliate thereof in the Change of Control
transaction, or if the assumed or substituted awards fail to contain similar terms and conditions as the Award prior to the Change
of Control or fail to preserve, to the extent applicable, the benefit to be provided to the Participant as of the date of the Change
of Control, including but not limited to the right of the Participant to receive shares upon exercise of the Option or SAR that
are registered for sale to the public pursuant to an effective registration statement filed with the U.S. Securities and Exchange
Commission, then (1) each holder of an Option or SAR that is outstanding as of the date of the Change of Control who is an employee
of the Company or any Subsidiary shall have the right, and (2) the Committee, in its sole discretion, may grant to a holder of
an Option or SAR that is outstanding as of the date of the Change of Control who is not an employee of the Company or any Subsidiary
the right, exercisable by written notice to the Company (or its successor in the Change of Control transaction) within 30 days
after the Change of Control (but not beyond the Option's or SAR's expiration date), to receive, in exchange for the surrender of
the Option or SAR, an amount of cash equal to the excess of the greater of the Fair Market Value of the Shares determined on the
Change of Control date or the Fair Market Value of the Shares on the date of surrender covered by the Option or SAR (to the extent
vested and not yet exercised) that is so surrendered over the purchase or grant price of such Shares under the Award. If the Committee
so determines prior to the Change of Control, any such Option or SAR that is not exercised or surrendered prior to the end of such
30- day period will be cancelled.

 

    	 	16	 

     

    

  

(iii)
If, in connection with the Change of Control, the Shares issued to a Participant as a result of the accelerated vesting or payment
of a Restricted Stock Award, Performance Share Award, Restricted Stock Unit Award, Performance Unit Award or Dividend Equivalent
Award under this subsection (c) are not registered for sale to the public pursuant to an effective registration statement filed
with the U.S. Securities and Exchange Commission, then each holder of such Shares shall have the right, exercisable by written
notice to the Company (or its successor in the Change of Control transaction) within 30 days after the Change of Control, to receive,
in exchange for the surrender of such Shares an amount of cash equal to the greater of the Fair Market Value of a Share on the
Change of Control date or the Fair Market Value of such Share on the date of surrender.

 

The
provisions of Sections 16(c)(ii) and (iii) shall govern the treatment of awards made under the 2010 Plan and 2013 Plan in the event
of a Change of Control, and the 2010 Plan and 2013 Plan are each deemed amended accordingly.

 

(d)
Parachute Payment Limitation.

 

(i)
Scope of Limitation.
This Section 16(d) shall apply to an Award only if:

 

(A)
 the independent auditors most recently selected by the Board (the "Auditors")
determine that the after-tax value of such Award to the Participant, taking into account the effect of all federal, state and local
income taxes, employment taxes and excise taxes applicable to the Participant (including the excise tax under Code Section 4999),
will be greater after the application of this Section 16(d) than it was before the application of this Section 16(d); or

 

(B)
 the Committee, at the time of making an Award under the Plan or at any time thereafter,
specifies in writing that such Award shall be subject to this Section 16(d) (regardless of the after-tax value of such Award to
the Participant).

 

If
this Section 16(d) applies to an Award, it shall supersede any contrary provision of the Plan or of any Award granted under the
Plan.

 

(ii)
 Basic Rule.
Except as may be set forth in a written agreement by and between the Company and the holder of an Award, in the event that the
Auditors determine that any payment or transfer by the Company under the Plan to or for the benefit of a Participant (a "Payment")
would be nondeductible by the Company for federal income tax purposes because of the provisions concerning "excess parachute
payments" in Code Section 280G, then the aggregate present value of all Payments shall be reduced (but not below zero) to
the Reduced Amount. For purposes of this Section 16(d), the "Reduced Amount" shall be the amount, expressed as a present
value, which maximizes the aggregate present value of the Payments without causing any Payment to be nondeductible by the Company
because of Code Section 280G.

 

    	 	17	 

     

    

 

(iii)
Reduction of Payments.
If the Auditors determine that any Payment would be nondeductible by the Company because of Code Section 280G, then the Company
shall promptly give the Participant notice to that effect and a copy of the detailed calculation thereof and of the Reduced Amount,
and the Participant may then elect, in his or her sole discretion, which and how much of the Payments shall be eliminated or reduced
(as long as after such election the aggregate present value of the Payments equals the Reduced Amount) and shall advise the Company
in writing of his or her election within ten (10) days of receipt of notice. If no such election is made by the Participant within
such ten (10) day period, then the Company may elect which and how much of the Payments shall be eliminated or reduced (as long
as after such election the aggregate present value of the Payments equals the Reduced Amount) and shall notify the Participant
promptly of such election. For purposes of this Section 16(d), present value shall be determined in accordance with Code Section
280G(d)(4). All determinations made by the Auditors under this Section 16(d) shall be binding upon the Company and the Participant
and shall be made within sixty (60) days of the date when a Payment becomes payable or transferable. As promptly as practicable
following such determination and the elections hereunder, the Company shall pay or transfer to or for the benefit of the Participant
such amounts as are then due to him or her under the Plan and shall promptly pay or transfer to or for the benefit of the Participant
in the future such amounts as become due to him or her under the Plan.

 

(iv)
Overpayments and Underpayments.
As a result of uncertainty in the application of Code Section 280G at the time of an initial determination by the Auditors hereunder,
it is possible that Payments will have been made by the Company that should not have been made (an "Overpayment") or
that additional Payments that will not have been made by the Company could have been made (an "Underpayment"), consistent
in each case with the calculation of the Reduced Amount hereunder. In the event that the Auditors, based upon the assertion of
a deficiency by the Internal Revenue Service against the Company or the Participant that the Auditors believe has a high probability
of success, determine that an Overpayment has been made, such Overpayment shall be treated for all purposes as a loan to the Participant
which he or she shall repay to the Company, together with interest at the applicable federal rate provided in Code Section 7872(f)(2);
provided, however, that no amount shall be payable by the Participant to the Company if and to the extent that such payment would
not reduce the amount subject to taxation under Code Section 4999. In the event that the Auditors determine that an Underpayment
has occurred, such Underpayment shall promptly be paid or transferred by the Company to or for the benefit of the Participant,
together with interest at the applicable federal rate provided in Code Section 7872(f)(2).

 

    	 	18	 

     

    

  

(v)
Related Corporations. For purposes of this Section 16(d),
the term "Company" shall include affiliated corporations to the extent determined by the Auditors in accordance with
Code Section 280G(d)(5).

 

17.
Miscellaneous.

 

(a)
Other Terms and Conditions. The grant of any Award may also
be subject to other provisions (whether or not applicable to the Award granted to any other Participant) as the Committee determines
appropriate, including, without limitation, provisions for:

 

(i)
one or more means to enable Participants to defer the delivery of Shares or recognition of
taxable income relating to Awards or cash payments derived from the Awards on such terms and conditions as the Committee determines,
including, by way of example, the form and manner of the deferral election, the treatment of dividends paid on the Shares during
the deferral period or a means for providing a return to a Participant on amounts deferred, and the permitted distribution dates
or events (provided that if Shares would have otherwise been issued under an Award but for the deferral described in this paragraph,
then such Shares shall be treated as if they were issued for purposes of Sections 6(a));

 

(ii)
 the payment of the purchase price of Options by delivery of cash or other Shares or
other securities of the Company (including by attestation) having a then Fair Market Value equal to the purchase price of such
Shares, or by delivery (including by fax) to the Company or its designated agent of an executed irrevocable option exercise form
together with irrevocable instructions to a broker dealer to sell or margin a sufficient portion of the Shares and deliver the
sale or margin loan proceeds directly to the Company to pay for the exercise price;

 

(iii)
conditioning the grant or benefit of an Award on the Participant's agreement to comply with
covenants not to compete, not to solicit employees and customers and not to disclose confidential information that may be effective
during or after the Participant's employment or service, and/or provisions requiring the Participant to disgorge any profit, gain
or other benefit received in connection with an Award as a result of the breach of such covenant;

 

(iv)
the automatic grant of a new Option (the "replenishment Option") to a Participant
who pays the exercise price of an existing Option in Shares; provided that the replenishment Option shall cover only that number
of Shares that is used to pay the exercise price and shall expire at the same time as the original Option to which it relates;

 

    	 	19	 

     

    

  

(v)
 restrictions on resale or other disposition of Shares, including imposition of a retention
period; and

 

(vi)
compliance with federal or state securities laws and stock exchange requirements.

 

(b)
Employment or Service.
The issuance of an Award shall not confer upon a Participant any right with respect to continued employment or service with the
Company or any Affiliate, or the right to continue as a Director. Unless determined otherwise by the Committee, for purposes of
the Plan and all Awards, the following rules shall apply:

 

(i)
a Participant who transfers employment between the Corporation and any Affiliate of the Company,
or between the Company's Affiliates, will not be considered to have terminated employment;

 

(ii)
 a Participant who ceases to be a Non-Employee Director because he or she becomes an
employee of the Company or an Affiliate shall not be considered to have ceased service as a Director with respect to any Award
until such Participant's termination of employment with the Company and its Affiliates;

 

(iii)
a Participant who ceases to be employed by the Company or an Affiliate of the Company and
immediately thereafter becomes a Non-Employee Director, a non- employee director of any Affiliate, or a consultant to the Company
or any Affiliate shall not be considered to have terminated employment until such Participant's service as a director of, or consultant
to, the Company and its Affiliates has ceased; and

 

(iv)
a Participant employed by an Affiliate of the Company will be considered to have terminated
employment when such entity ceases to be an Affiliate of the Company.

 

Notwithstanding
anything herein contained to the contrary, for purposes of an Award that is subject to Code Section 409A, if a Participant's termination
of employment or service triggers the payment of compensation under such Award, then the Participant will be deemed to have terminated
employment or service upon his or her "separation from service" within the meaning of Code Section 409A. Notwithstanding
any other provision in this Plan or an Award to the contrary, if any Participant is a "specified employee" within the
meaning of Code Section 409A as of the date of his or her "separation from service" within the meaning of Code Section
409A, then, to the extent required by Code Section 409A, any payment made to the Participant on account of such separation from
service shall not be made before a date that is six months after the date of the separation from service.

 

(c)
No Fractional Shares.
No fractional Shares or other securities may be issued or delivered pursuant to this Plan, and the Committee may determine whether
cash, other securities or other property will be paid or transferred in lieu of any fractional Shares or other securities, or whether
such fractional Shares or other securities or any rights to fractional Shares or other securities will be canceled, terminated
or otherwise eliminated.

 

    	 	20	 

     

    

  

(d)
Unfunded Plan.
This Plan is unfunded and does not create, and should not be construed to create, a trust or separate fund with respect to this
Plan's benefits. This Plan does not establish any fiduciary relationship between the Company and any Participant or other person.
To the extent any person holds any rights by virtue of an Award granted under this Plan, such rights are no greater than the rights
of the Company's general unsecured creditors.

 

(e)
Requirements of Law and Securities Exchange.
The granting of Awards and the issuance of Shares in connection with an Award are subject to all applicable laws, rules and regulations
and to such approvals by any governmental agencies or national securities exchanges as may be required. Notwithstanding any other
provision of this Plan or any Award Agreement, the Company has no liability to deliver any Shares under this Plan or make any payment
unless such delivery or payment would comply with all applicable laws and the applicable requirements of any securities exchange
or similar entity, and unless and until the Participant has taken all actions required by the Company in connection therewith.
The Company may impose such restrictions on any Shares issued under the Plan as the Company determines necessary or desirable to
comply with all applicable laws, rules and regulations or the requirements of any national securities exchanges.

 

(f)
Governing Law.
This Plan, and all agreements under this Plan, will be construed in accordance with and governed by the laws of the State of Delaware,
without reference to any conflict of law principles. The parties agree that the exclusive venue for any legal action or proceeding
with respect to this Plan, any Award or any Award Agreement, or for recognition and enforcement of any judgment in respect of this
Plan, any Award or any Award Agreement, shall be a court sitting in the County of Los Angeles, or the Federal District Court for
the Central District of California sitting in the County of Los Angeles, in the State of California, and further agree that any
such action may be heard only in a "bench" trial, and any party to such action or proceeding shall agree to waive its
right to assert a jury trial.

 

(g)
Limitations on Actions.
Any legal action or proceeding with respect to this Plan, any Award or any Award Agreement, must be brought within one year (365
days) after the day the complaining party first knew or should have known of the events giving rise to the complaint.

 

(h)
Construction.
Whenever any words are used herein in the masculine, they shall be construed as though they were used in the feminine in all cases
where they would so apply; and wherever any words are used in the singular or plural, they shall be construed as though they were
used in the plural or singular, as the case may be, in all cases where they would so apply. Titles of sections are for general
information only, and this Plan is not to be construed with reference to such titles.

 

    	 	21	 

     

    

  

(i)
Severability. If any provision of this Plan or any Award
Agreement or any Award (i) is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction, or as to any
person or Award, or (ii) would disqualify this Plan, any Award Agreement or any Award under any law the Committee deems applicable,
then such provision should be construed or deemed amended to conform to applicable laws, or if it cannot be so construed or deemed
amended without, in the determination of the Committee, materially altering the intent of this Plan, Award Agreement or Award,
then such provision should be stricken as to such jurisdiction, person or Award, and the remainder of this Plan, such Award Agreement
and such Award will remain in full force and effect.

 

ADOPTED
BY BOARD OF DIRECTORS: December 15, 2015

 

    	 	22Exhibit 10.60

 

ASSET PURCHASE AGREEMENT

 

This
Asset Purchase Agreement dated as of January 12, 2016 (this “Agreement”) is executed by and among Apollo Medical Holdings,
Inc., a Delaware corporation (“Apollo”), Apollo Care Connect, Inc., a Delaware corporation and a wholly-owned subsidiary
of Apollo (individually, “Acquisition” and together with Apollo, “Purchaser”), and Healarium, Inc., a Delaware
corporation (“Seller” or “Healarium”). 

 

RECITALS

 

WHEREAS,
Purchaser wishes to acquire from Seller, and Seller wishes to sell to Purchaser, certain assets used in the population health services
business; and 

 

WHEREAS,
Apollo has organized Acquisition as a wholly-owned subsidiary for the purpose of completing such purchase (the “Transaction”);
and

 

WHEREAS,
on the terms and subject to the conditions set forth in this Agreement, the Seller desires to sell to the Purchaser, and the Purchaser
desires to purchase from the Seller, the Assets (as defined in Section 1(a) below).

 

NOW THEREFORE, in consideration of the mutual
promises of the parties, and in reliance on the representations, warranties, covenants and conditions contained herein, and for
other good and valuable consideration, the parties hereto hereby agree as follows:

 

1.          Sale
and Purchase of Assets.

 

a.           Subject to the terms and
conditions of this Agreement, at the Closing (as defined in Section 3 below), Seller shall sell, convey, assign, transfer, set
over and deliver to Purchaser, and Purchaser shall purchase and acquire all of Seller’s right, title and interest in and
to the Assets, as defined on Schedule “I” attached hereto, the terms of which are incorporated herein by this
reference, free and clear of any and all security interests, assignments, pledges, hypothecations, mortgages, liens (including
environmental and tax liens), violations, charges, licenses, encumbrances, claims or potential claims of co-ownership or co-creation
of Intellectual Property (as defined in Schedule “I”), other claims, reversions, reverters, preferential arrangements,
restrictive covenants, conditions or restrictions of any kind, including any restrictions on the use, transfer, receipt of income
or other exercise of any attributes of ownership (collectively, “Encumbrances”).

 

    	 	1	 

     

    

 

b.           Excluded
Assets. Notwithstanding anything to the contrary, the assets listed on Schedule “I” as being retained by Seller
(collectively, the “Excluded Assets”) shall not be part of the Assets being sold by the Seller and purchased by the
Purchaser hereunder; provided, however, that in the event that (i) Seller decides to sell the Excluded Assets, or any portion thereof,
to a third party, or (ii) receives a bona fide offer from a third party to purchase the Excluded Assets, or any portion thereof,
Seller shall first offer Purchaser a right of first refusal (a “ROFR”) to purchase such assets on such terms as the
parties may agree as a result of good faith negotiations; provided, however, that such terms are as favorable as the offer received
from such third party (if any). Upon receipt of notice from Seller (the “Seller ROFR Notice”), Purchaser shall have
twenty (20) days (the “ROFR Notice Period”) to elect to purchase all (but not less than all) the assets offered in
the Seller ROFR Notice by delivering written notice (the “Purchaser ROFR Notice”) to the Seller. If Purchaser does
not deliver the Purchaser ROFR Notice during the ROFR Notice Period in accordance with this Section 1(b), Purchaser shall have
been deemed to have waived all such rights to purchase the Excluded Assets under this this Section 1(b) and Seller shall be free
to sell the Excluded Assets to the original third party without any further obligation to the Purchaser pursuant to this Section
1(b), provided further that such sale takes place within sixty (60) days following the end of the ROFR Notice Period. After such
date, Purchaser’s ROFR pursuant to this Section 1(b) shall again apply.

 

c.           No
Liabilities Assumed. Purchaser shall not assume or be responsible at any time for any liability, obligation, debt or other commitment
of Seller, whether absolute or contingent, accrued or unaccrued, asserted or unasserted, or otherwise, including but not limited
to any liabilities, obligations, debts or commitments of Seller incident to, arising out of or incurred with respect to, this Agreement
or the Assets conveyed and the Transaction contemplated hereby, including without limitation, any and all taxes (including bulk
sales taxes, if any) arising out of the Transaction contemplated hereby (collectively, “Excluded Obligations”).

 

2.          Transaction.

 

a.           Subject to subsection (b)
of this Section 2, the purchase price for the Assets (the “Purchase Price”), to be paid at the Closing, shall be as
follows:

 

i.            Purchaser
shall issue 275,000 duly issued and fully paid shares of the common stock of Apollo to Seller (the “Purchaser Closing Payment”);
and

 

ii.         Seller
shall pay Purchaser $200,000 (the “Seller Closing Payment”).

 

3.          Closing
and Deliveries.

 

a.           The
Closing. The closing of the Transaction (the “Closing”) shall take place at the offices of SEC Law Firm, 11693
San Vicente Boulevard, Suite 357, Los Angeles, California 90049, or at such other place, including pursuant to a “virtual
Closing”, as the parties may agree, simultaneously with the execution and delivery of this Agreement. . The date of the Closing
is referred to in this Agreement as the “Closing Date”.

 

    	 	2	 

     

    

 

b.           Deliverables
by Seller at the Closing. At or prior to the Closing, Seller shall deliver or cause to be delivered to Purchaser:

 

i.            A
functional, operational software operating platform (the “Platform”) that has been tested by Core Value, Inc.;

 

ii.         duly
executed Patent Assignments, substantially in the form attached hereto as Exhibit “A”, the terms of which are incorporated
herein by this reference, with respect to each patent application listed on Schedule “I” (individually, a “Patent
Application” and collectively, the “Patent Applications”) ;

 

iii.         a
CD and/or access to Cloud Storage containing all sources codes used in connection with the Intellectual Property or other Assets,
to the extent such exist;

 

iv.         a
Bill of Sale, substantially in the form attached hereto as Exhibit “B”, the terms of which are incorporated herein
by this reference, and/or such other instrument(s) of conveyance, assignment and transfer as Purchaser may reasonably request,
in form and substance satisfactory to Purchaser, as shall be effective to transfer and assign to, and vest in, Purchaser, the Assets
free and clear of any and all Liens;

 

v.           an
Officer’s Certificate, duly executed on Seller’s behalf, as to whether each condition specified in this Agreement has
been satisfied in all respects by Seller;

 

vi.         a
certificate changing Seller’s corporate name to a name as determined by Seller but which names shall not include the words
“Healarium” or any similar or derivative name(s) or variations thereof; and

 

viii.         The
Seller Closing Payment, except that the Seller Closing Payment shall be received by Purchaser within three (3) business days following
the Closing Date, which shall constitute timely delivery thereof.

 

c.           Deliverables
by Purchaser at the Closing. At or prior to the Closing, Purchaser shall deliver or cause to be delivered to Seller:

 

i.            a
stock certificate registered in the name of Seller, evidencing the Purchaser Closing Payment, except that the Purchase Closing
Payment shall be received by Seller within three (3) business days following the Closing Date, which shall constitute timely delivery
thereof; and

 

ii.         an
Officer’s Certificate, duly executed on Purchaser’s behalf, as to whether each condition specified in this Agreement,
been satisfied in all respects by Purchaser.

 

    	 	3	 

     

    

 

d.           Third Party Consents. To the extent that either Seller's rights under any agreement, commitment, or other Asset being
sold to and purchased by Purchaser hereunder may not be assigned by Seller without the consent (“Consent”) of another
person or entity which has not been obtained, this Agreement shall not constitute an agreement to assign the same if an attempted
assignment would constitute a breach thereof or be unlawful, and Seller, at its expense, shall use best efforts to obtain any such
required Consent as promptly as possible. If any such Consent is not obtained, or if any attempted assignment would be ineffective
or would impair Purchaser’s rights under the Asset so that Purchaser would not in effect acquire the benefit of all such
rights, Seller shall, to the maximum extent permitted by law and the Asset, act after the Closing as Purchaser’s agent in
order to obtain for Purchaser the benefits thereunder and shall cooperate, to the maximum extent permitted by law, with Purchaser
in any other reasonable arrangement designed to provide such benefits to Purchaser.

 

e.           Seller’s Further
Assurances. Seller from time to time at and after the Closing shall execute, acknowledge and deliver to Purchaser such other
instruments of conveyance and transfer and shall take such other actions and execute and deliver such other documents, certificates
and further assurances as Purchaser reasonably may request in order to vest more effectively in Purchaser, or to put Purchaser
more fully in possession of, the Assets.

 

f.
           Failure to Deliver Deliverables On Time. Time is of the essence in respect
of the delivery of each deliverable by each party pursuant to this Section 3. If one party fails to deliver any of its deliverables
by the respective deadlines provided for in this Section 3 (the “Breaching Party”), the other party (the Non-Breaching
Party”) shall have the right, at any time thereafter, in its sole and absolute discretion, by giving written notice to the
Breaching Party, to rescind the Transaction in toto as its exclusive remedy for such breach. In such event, and irrespective
of fault, the parties shall fully cooperate with each other to return, each to the other, every item of value each has received
theretofore with respect to the Transaction, including without limitation, the Assets, the Purchaser Closing Payment and/or the
Seller Closing Payment. The failure of any party to return the items provided for in the preceding sentence shall constitute a
material breach of this Agreement by such party, whether such party is the Breaching Party or the Non-Breaching Party.

 

    	 	4	 

     

    

 

4.          Representations
and Warranties of Seller. 

 

Seller represents and warrants
to each of Apollo and Acquisition as follows:

 

a.           Organization,
Standing and Corporate Power. Seller is a corporation duly organized, validly existing and in good standing under the laws
of the jurisdiction of its organization and has all requisite power and authority to own, lease and operate its properties and
assets and to carry on its business as now being conducted. Complete and correct copies of the charter documents of Seller have
been delivered to Purchaser or its counsel.

 

b.           Authority;
Enforceability; Effect of Agreement.

 

i.            Seller
has full power and authority to enter into, execute and deliver this Agreement and perform its obligations hereunder and the other
agreement, documents and instruments contemplated hereby. This Agreement has been duly authorized by all necessary corporate action
of Seller, including, without limitation, the authorization and approval by its shareholders, if required by the Delaware General
Corporation Law, and its Board of Directors . This Agreement has been duly executed and delivered by Seller and, assuming this
Agreement is duly executed and delivered by Purchaser, constitutes a valid and legally binding obligation of Seller enforceable
against it in accordance with its terms, subject to the effect of bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance and other similar laws relating to or affecting creditors’ rights generally, or the availability of equitable
remedies.

 

ii.         The
execution and delivery by Seller of this Agreement do not, and compliance by Seller with the provisions of this Agreement will
not, (a) conflict with or result in a breach or default under any of the terms, conditions or provisions of any contract to which
Seller is a party or otherwise bound, or to which any property or asset of Seller is subject; (b) violate any law applicable to
Seller; or (c) result in the creation or imposition of any claim, lien or Encumbrance on any asset of Seller, including the Assets.

 

c.           Assets.
Seller has, and at the Closing Purchaser will convey
to Seller, good, valid and marketable title to each of the Assets, free and clear of any claim, lien or Encumbrance of any kind.

 

    	 	5	 

     

    

 

d.           Intellectual
Property.

 

i.            
Seller has not received any written notice of (or is aware of any) infringement or other written complaint to the effect that
Seller or any of its Affiliates has violated or infringed the intellectual property or any other proprietary rights of others.
Seller owns each item of Intellectual Property free and clear of all claims, liens and Encumbrances. Neither Seller nor any of
its Affiliates has wrongfully exploited any Intellectual Property owned or licensed by any person for which Seller could suffer
any damages, and neither Seller nor any person employed by or Affiliated with Seller has violated any confidential relationship
which such person may have had with any third party for which Seller could suffer any damages. Seller has full right and authority
to utilize the Intellectual Property. No royalties, honoraria, damages or fees are payable by Seller or any of its Affiliates to
other persons by reason of the ownership or use of the Intellectual Property. No Affiliate of Seller owns or holds, directly or
indirectly, any interests in the Intellectual Property. To Seller’s best knowledge, no person has interfered with, infringed
upon, misappropriated, or otherwise violated any intellectual property right of Seller. Seller (i) owns or has the right to use
all Intellectual Property and Licensed Technology used in or necessary for the conduct of the business of Seller without, to Seller's
best knowledge, infringing upon or otherwise acting adversely to the right or claimed right of any person under or with respect
to any of the foregoing and (ii) is not obligated or under any liability to make any payments by way of royalties, fees or otherwise
to any owner or licensee of, or other claimant to, any Intellectual Property. For all purposes of this Agreement, the term “Affiliate”
means a person controlling, controlled by, or under common control with, another person.

 

ii.           
The Patent Applications
consist of the entire right, title and interest in and to said invention or inventions, as described in the applications for the
patents filed with the United States Patent and Trademark Office; and in and to any application filed in any foreign country based
thereon, including the right to file foreign applications under the provisions of the any international law or treaty; also the
entire right, title and interest in and to any and all patents or reissues or extensions thereof to be obtained in this or any
foreign country upon said invention or inventions and any divisional, continuation, continuation-in-part or substitute applications
which may be filed upon said invention or inventions in the or any foreign country. Seller has abandoned prosecution of the patents
and has made no other attempts to prosecute the patents, including without limitation any derivative intellectual property, anywhere
in the world.

 

e.           
Licensed Technology.
All Licensed Technology (as defined in Schedule “I”) has been duly licensed by Seller from the third party owner
thereof, and Seller’s use of each item of Licensed Technology is authorized. To Seller’s best knowledge, no person
has interfered with, infringed upon, misappropriated, or otherwise violated any intellectual property right of the owner(s) of
such Licensed Technology.

 

    	 	6	 

     

    

 

  f.            Litigation and Proceedings. There is no pending or, to the best knowledge of Seller, threatened action or proceeding (or basis for any action or proceeding), to which Seller is a party or involving any of the Assets or which could materially affect Seller’s ability to execute and deliver this Agreement or to perform each of its obligations contemplated hereby. Seller is not subject to any judgment, order, writ, injunction, decree or regulatory directive or agreement preventing them from executing, delivering and performing its obligations under this Agreement and the other agreements, documents and instruments contemplated hereby.

 

g.            Compliance with Laws.
Seller and its predecessors and Affiliates have complied with all applicable laws applicable to them in the ownership and use of
the Assets, and no action is pending or, to the best knowledge of Seller, threatened (and there is no basis therefor) against any
of them alleging any failure to so comply.

 

h.            Creditor Issues.
The sale of Assets to the Purchaser is not being made with the intent to hinder, delay or defraud any creditor of Seller. Seller
believes, in good faith, that it is receiving reasonably equivalent value in exchange for the transfer of the Assets. Seller is
not insolvent nor will become insolvent as a result of the Transaction.

 

i.            No
Conflicts; No Consents Required. There are no approvals, authorizations, Consents, orders or other actions of, or filings with,
any person, entity (governmental or otherwise) or organization that are required to be obtained or made by Seller in connection
with the execution of, and the consummation of the Transactions contemplated under, this Agreement, including, without limitation,
the effective transfer to Purchaser of the Assets. The execution, delivery and performance of this Agreement and the Transaction
contemplated hereby by Seller does not, and will not (with or without the giving of notice or the passage of time, or both), violate,
conflict with, result in a breach or default under, give rise to any rights of acceleration, modification, termination or cancellation
of, result in the creation of any claim, lien or Encumbrance pursuant to, or require any notice or consent under the charter or
bylaws of Seller, or any mortgage, indenture, instrument, agreement, understanding or commitment of any kind, or any law, regulation,
rule, order, judgment or decree, to which Seller is a party or by which Seller is bound or affected, other than such notices and
consents which have been given or obtained. No authorization, permit, approval or consent of, and no registration or filing with
any governmental or regulatory authority is required in connection with the execution, delivery and performance by Seller of the
sale and transfer of Assets to Purchaser.

 

j.            Material Misstatements
and Omissions. No representations and warranties by Seller in this Agreement contains any untrue statement of material fact
or, to the knowledge of Seller, omits to state any material fact to make the statements made therein, in light of the circumstances
under which they were made, misleading.

 

    	 	7	 

     

    

 

k.          Securities
Representations.

 

(i)          Investment
Intent. Healarium is acquiring the shares of Apollo’s common stock being issued to it as the Purchaser Closing Payment
(the “Securities”), for investment as principal for its own account, not as nominee or agent, and not with a view to,
or for resale of any part thereof in connection with, any distribution or public offering thereof within the meaning of the Securities
Act of 1933, as amended, (the “Securities Act”) or applicable state securities laws, and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation
of the Securities Act or applicable state securities law.

 

(ii)          Knowledge and Experience.
Healarium, either alone or together with its representatives, (A) has such knowledge and experience in financial and business matters
generally and about Apollo specifically as to be capable of evaluating the merits and risks of the Securities; and (B) has the
ability to bear the economic risk of holding the Securities, including the complete loss of its investment therein.

 

(iii)        Access
to Information. Healarium acknowledges that it has had the opportunity to review Apollo’s periodic reports and other
filings made from time to time with the Commission and has been afforded (A) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of Apollo concerning the terms and conditions of the offering of the
Securities and the merits and risks of investing in the Securities; (B) access to information about Apollo, including its subsidiaries
and consolidated Affiliates, and their respective financial condition, results of operations, business, properties, management
and prospects sufficient to enable it to evaluate its investment; and (C) the opportunity to obtain such additional information
that Healarium possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment
decision with respect to an investment in the Securities. Healarium has had the opportunity to seek such accounting, legal and
tax advice, at its own expense, as it has considered necessary to make an informed decision with respect to its acquisition of
the Securities.

 

(iv)        No
Governmental Review. Healarium understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(v)          No Solicitation.
Healarium has not been offered the Securities, or any part thereof, by any form of advertisement, article, notice or other communication
published in any newspaper, magazine, or similar media or broadcast over television or radio, or any seminar or meeting whose attendees
have been invited by any such media. Healarium became interested in Apollo’s Securities through means other than Apollo’s
Registration Statement on Form S-1, including any amendment thereto (collectively, the “S-1”) filed with the Commission,
was not identified, contacted or solicited through the marketing of the S-1, and did not independently contact Apollo as a result
of any solicitation in connection with the S-1.

 

    	 	8	 

     

    

 

(vi)        Certain
Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, Healarium has not directly
or indirectly, nor has any person acting on behalf of or pursuant to any understanding with Healarium, executed any purchases or
sales, including short sales, of any of Apollo’s securities during the period commencing as of the time that Healarium and
Apollo first entered into the Non-Disclosure Agreement (as defined in Section 6(a)(i)) through and including the Closing Date.
Other than to its professional advisors, Healarium has maintained the confidentiality of all disclosures made to it in connection
with this transaction.

 

(vii)       Securities
Not Registered. Healarium understands and acknowledges that the Securities issued to it by Apollo pursuant to this Agreement
will not be registered under the Securities Act or qualified under any state securities laws on the basis that the offering and
sale of the Securities contemplated by this Agreement are exempt from registration under the Securities Act and exempt from qualification
under applicable state securities laws, and that Apollo’s reliance upon such exemptions is predicated, in part, upon Healarium's
representations set forth in this Section 4(k). Healarium understands that the Securities are “restricted securities”,
and have not been, are not being, and Healarium expects will not be, registered under the Securities Act or any applicable state
securities laws. Healarium acknowledges and understands that the resale of the Securities may be restricted indefinitely unless
the Securities are subsequently registered under the Securities Act and qualified under applicable state securities laws, or an
exemption from such registration and such qualification is available. Healarium understands and acknowledges that it does not have
registration rights with respect to the Securities and Apollo has no present intention of registering the Securities. Healarium
further understands and acknowledges that any sale of the Securities made in reliance on Rule 144 under the Securities Act will
be subject to the requirements of Rule 144(i) because Apollo was previously an issuer described in paragraph (i)(1)(i) of Rule
144.

 

(viii)      Legend.
Healarium understands that the certificate evidencing the Securities shall bear a restrictive legend in substantially the following
form (and a stop-transfer order may be placed against transfer of the certificates for such Securities by Apollo’s transfer
agent):

 

“THESE SECURITIES HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED FOR SALE UNDER ANY STATE SECURITIES LAWS (COLLECTIVELY,
“SECURITIES LAWS”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT AND QUALIFICATION FOR SALE UNDER ALL APPLICABLE SECURITIES LAWS, OR UNLESS, IN THE OPINION OF COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER, ANY SUCH OFFER, SALE OR OTHER TRANSFER IS EXEMPT FROM THE REGISTRATION OR QUALIFICATION REQUIREMENTS
OF SUCH SECURITIES LAWS.”

 

    	 	9	 

     

    

 

5.          
Representations and Warranties of Purchaser. 

 

Apollo and Acquisition, jointly and severally,
represent and warrant to Seller as follows:

 

a.           Organization,
Standing and Corporate Power. Each of Apollo and Acquisition is a corporation duly organized, validly existing and in good
standing under the laws of the state of its respective incorporation and has all requisite power and authority to own, lease and
operate its respective properties and assets and to carry on its respective business as now being conducted. Acquisition is a wholly-owned
subsidiary of Apollo.

 

b.           Authority;
Enforceability; Effect of Agreement.

 

i.            Each
of Apollo and Acquisition has full power and authority to enter into, execute and deliver this Agreement and perform its respective
obligations hereunder. This Agreement has been duly authorized by all necessary action of Apollo and Acquisition. This Agreement
has been duly executed and delivered by Apollo and Acquisition and constitutes a valid and legally binding obligation of each of
them and is enforceable against each of them in accordance with its terms, subject to the effect of bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance and other similar laws relating to or affecting creditors’ rights generally, or the availability
of equitable remedies.

 

ii.         The
execution and delivery by the Apollo and Acquisition of this Agreement do not, and compliance by Apollo and Acquisition with the
provisions hereof will not, (a) conflict with or result in a breach or default under any of the terms, conditions or provisions
of any contract to which Apollo or Acquisition is a party or otherwise bound, or to which any of the respective assets or properties
of Apollo or Acquisition are subject; or (b) violate any law applicable to Apollo or Acquisition; or (c) result in the creation
or imposition of any lien on any of the respective assets of Apollo or Acquisition.

 

c.           Reports.
Apollo has timely filed or furnished all reports (“Apollo Reports”) required to be filed by it with the Securities
and Exchange Commission (the “Commission”), all of which have complied as of their respective filing dates in all material
respects with all then applicable requirements of the Securities Exchange Act of 1934, as amended. None of the Apollo Reports,
at the time filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
As of the date of this Agreement, there are no outstanding or unresolved comments received from the Staff of the Commission with
respect to any of the Apollo Reports.

 

    	 	10	 

     

    

 

			6.          Further Agreements of the Parties.

 

a.           Confidentiality.

 

i.            The
Parties acknowledge that Seller and Purchaser have previously entered into that certain Mutual Non-Disclosure Agreement dated December
15, 2015 (the “Non-Disclosure Agreement”), a copy of which is attached hereto as Exhibit “C”, and the terms
of which are incorporated herein by this reference. The terms of the Non-Disclosure Agreement shall survive the termination of
this Agreement and the Closing hereunder.

 

ii.            No party shall be entitled, without the
prior approval of the other parties, to issue any press release or other public disclosure with respect to the Transaction; except
that Apollo shall make such disclosures, without the consent of the other parties, as Purchaser, or its counsel, determine are
necessary to comply with Federal securities laws, the Rules and Regulations of the Commission and the requirements of any exchange
on which any of its securities are listed or quoted.

 

b.            Expenses. Except
as otherwise expressly provided in this Agreement, Seller, on the one hand, and Purchaser, on the other hand, will each bear its
own costs and expenses incurred in connection with the preparation, execution and performance of this Agreement and the Transaction
contemplated hereby including all fees and expenses of agents, representatives, financial advisors, legal counsel and accountants.

 

c.            Further
Assurances. Each party agrees, without further consideration, from time to time after the Closing to (i) execute and
deliver further instruments of transfer, assumption and assignment and take such other actions as the other party may
reasonably require to transfer, assign to and vest in Purchaser the Assets, including; (ii) cooperate with and provide
assistance to the other party in transferring possession of the Assets to Purchaser and (iii) do, execute, acknowledge and
deliver, or cause to be done, executed, acknowledged and delivered, all and every further reasonable act, deed, conveyance,
transfer and assurance necessary to assure their compliance with the terms, provisions, purposes and intents of this
Agreement and the effectiveness of the rights, benefits and remedies provided for hereby; it being understood that no party
shall be required to expend money, commence any litigation or offer or grant any accommodation (financial or otherwise) to
any Third Party in connection with this Section 6(c).

 

    	 	11	 

     

    

 

d.           No
Brokers. The Parties represent and warrant to each other that no brokers were used in connection with this Agreement and the
Transaction contemplated herein, and no amount is due or owing to any such person.

 

e.           Purchase
Price Allocation. The Parties agree to allocate the Purchase Price or other payments made hereunder by mutual agreement based
on the fair market values of the assets transferred. Each Party agrees that it will not take any position for purposes of computing
federal or state income tax or franchise taxes that is inconsistent with the agreed upon allocations, unless such allocations are
determined, in good faith, to be violative of federal, state or local law. If any Party fails to comply with this Section 6(e),
such Party shall be liable for all taxes, legal and accounting fees, and other expenses actually incurred by the other Party as
a consequence of such failure.

 

f.            Technical
Assistance. For a period of six (6) months following the Closing Date, Seller shall make available to Purchaser, upon request,
any then current employee, or use commercially reasonable effort to make available to Purchaser any independent contractor, of
Seller for the purpose of providing technical assistance with respect to the Assets.

 

g.           CareHere
Agreement. Notwithstanding anything to the contrary provided herein, Apollo and Purchaser will allow Seller to perform its
obligations under that certain Software License & Services Agreement by and between Seller and CareHere, LLC entered into June
23, 2011, and all amendments and exhibits thereto (collectively, the “CareHere Agreement”), until the CareHere Agreement
expires under its terms.

 

h.           Covenant
Not to Compete. In connection with Seller’s sale of the Assets to Purchaser, and as further consideration for Purchaser’s
purchase of the Assets, which Assets constitute substantially all of Seller’s assets in the operation of the population health
service business, Purchaser Seller agrees that for a period of two (2) years commencing on the Closing Date, neither it nor its
Affiliates shall, acting individually or as the director, officer, partner, employee or consultant of any entity, directly or indirectly,
engage in, operate or control a business in the population health services business anywhere in the United States, including its
territories and commonwealths. The parties agree and acknowledge that this provision is necessary and appropriate to protect the
interests of Purchaser and but for this provision Purchaser would not agree to purchase the Assets. In the event that it is determined
in a proceeding brought pursuant to this Agreement that this covenant is not enforceable in its entirety, this Section 6(h) shall
be modified by amending or striking one or more words to allow for the maximum application of this covenant in favor of Purchaser
without eliminating this Section 6(h) in its entirety.

 

    	 	12	 

     

    

 

i.            Contracts.
Seller shall deliver to Purchaser a copy of any Contract in Seller’s possession at the request of Purchaser.

 

7.          Survival
of Representations and Warranties; Indemnification.

 

a.           Survival
of Representations and Warranties. All representations and warranties made in this Agreement or made in any document delivered
pursuant to this Agreement by or on behalf of any Party shall survive the execution and delivery of this Agreement and the Closing,
regardless of notice of or any investigation or right of investigation made prior to or after the date of this Agreement by or
on behalf of any party, and shall terminate and expire two (2) years following the Closing Date (the “Survival Date”),
after which date they shall be of no further force or effect. No claim for a breach of any representation or warranties made in
this Agreement may be brought after the Survival Date, except for a claim for which a written notice, reasonably detailing the
basis therefor, shall have been delivered to the breaching party prior to the Survival Date; provided, that the Survival Date shall
not apply to any covenant or obligation of a party to be performed following Closing pursuant to the express terms hereof.

 

b.           Indemnification
By Seller. Seller shall indemnify, save and hold harmless Apollo and Acquisition, and each of their respective officers, directors,
employees, agents and Affiliates, and each of their successors and assigns (individually, a “Purchaser Indemnified Party”
and collectively, the “Purchaser Indemnified Parties”) from and against any and all costs, losses, claims, liabilities,
fines, penalties, consequential damages (other than lost profits), and expenses (including interest which may be imposed in connection
therewith and court costs and reasonable fees and disbursements of counsel) (“Damages”) incurred in connection with,
arising out of, resulting from or incident to:

 

i.            any
material breach of, or any inaccuracy in any of, the representations or warranties made by Seller in this Agreement, any exhibit
or schedule to this Agreement or any certificate, instrument or writing delivered in connection with this Agreement or in connection
with any exhibit or schedule to this Agreement;

 

ii.         any
default in any agreements made by Seller in this Agreement, any exhibit or schedule to this Agreement or any certificate, instrument
or writing delivered in connection with this Agreement or in connection with any exhibit or schedule to this Agreement; or

 

    	 	13	 

     

    

 

iii.         any
action, compromise, settlement, assessment or judgment arising out of or incidental to any of the matters indemnified against in
this section; provided, however, that Seller shall be obligated to indemnify a Purchaser Indemnified Party and hold it or him harmless
under this section with respect to any settlement of a claim to which Seller has not consented, which consent shall not unreasonably
be withheld, conditioned or delayed to the extent that such settlement does not impose on Seller any obligation other than the
indemnification obligations set forth herein. If, by reason of the claim of any third person relating to any of the matters subject
to indemnification under this section, a lien, attachment, garnishment or execution is placed upon any of the property or assets
of any Purchaser Indemnified Party, Seller shall also, promptly upon demand, furnish an indemnity bond (in an amount not exceeding
Seller’s then remaining indemnification obligations thereunder) satisfactory to the Purchaser Indemnified Party to obtain
the prompt release of such lien, attachment, garnishment or execution.

 

c.           Indemnification
by Purchaser. Apollo and Acquisition shall, jointly and severally, indemnify, save and hold harmless Seller and its officers,
directors, employees, agents and Affiliates, and each of their successors and assigns (individually, a “Seller Indemnified
Party” and collectively, the “Seller Indemnified Parties”) from and against any and all Damages incurred in connection
with, arising out of, resulting from or incident to:

 

i.            any
material breach of, or any inaccuracy in any of, the representations or warranties made by Apollo or Acquisition in this Agreement,
any exhibit or schedule to this Agreement or any certificate, instrument or writing delivered in connection with this Agreement
or in connection with any exhibit or schedule to this Agreement;

 

ii.         any
default in any agreements made by Apollo or Acquisition in this Agreement, any exhibit or schedule to this Agreement or any certificate,
instrument or writing delivered in connection with this Agreement or in connection with any exhibit or schedule to this Agreement;
or

 

iii.         any
action, compromise, settlement, assessment or judgment arising out of or incidental to any of the matters indemnified against in
this section; provided, however, that neither Apollo nor Acquisition shall be obligated to indemnify a Seller Indemnified Party
and hold it or him harmless under this section with respect to any settlement of a claim to which Apollo or Acquisition has not
consented, which consent shall not unreasonably be withheld, conditioned or delayed to the extent that such settlement does not
impose on Purchaser any obligation other than the indemnification obligations set forth herein. If, by reason of the claim of any
third person relating to any of the matters subject to indemnification under this section, a lien, attachment, garnishment or execution
is placed upon any of the property or assets of any Seller Indemnified Party, Apollo or Acquisition shall also, promptly upon demand,
furnish an indemnity bond (in an amount not exceeding Purchaser’s then remaining indemnification obligations thereunder)
satisfactory to the Seller Indemnified Party to obtain the prompt release of such lien, attachment, garnishment or execution.

 

    	 	14	 

     

    

 

d.           Notice
of Claim. If a claim for Damages (a “Claim”) is to be made by a party entitled to indemnification hereunder
(an “Indemnified Party”) against the indemnifying party (the “Indemnifying Party”), the Indemnified Party
shall give written notice (a “Claim Notice”) to the Indemnifying Party, which notice shall specify whether the Claim
arises as a result of a claim by a person against the Indemnified Party (a “Third Party Claim”) or whether the Claim
does not so arise (a “Direct Claim”), and shall also specify (to the extent that the information is available) the
factual basis for the Claim and the amount of the Damages, if known. If the Claim is a Third Party Claim, the Indemnified Party
shall provide the Claim Notice as soon as practicable after such party becomes aware of any fact, condition or event which may
give rise to Damages for which indemnification may be sought under this section. If any lawsuit or enforcement action is filed
against any Indemnified Party, written notice thereof shall be given to the Indemnifying Party as promptly as practicable (and
in any event within 15 calendar days after the service of the citation or summons). The failure of any Indemnified Party to give
timely notice hereunder shall not affect rights to indemnification hereunder, except to the extent that the Indemnifying Party
has been damaged by such failure.

 

e.           Direct
Claims. With respect to any Direct Claim, following receipt of the Claim Notice from the Indemnified Party, the Indemnifying
Party shall have 30 days to make such investigation of the Claim as is considered necessary or desirable. For the purpose of such
investigation, the Indemnified Party shall make available to the Indemnifying Party sufficient information to substantiate the
Claim, together with all such other non-privileged information as the Indemnifying Party may reasonably request. If both parties
agree at or prior to the expiration of such 30-day period (or any mutually agreed upon extension thereof) to the validity and amount
of such Claim, the Indemnifying Party shall immediately pay to the Indemnified Party the full agreed upon amount of the Claim.
If the parties have not so agreed to the validity and/or amount of the Claim, then the parties shall proceed in the manner set
forth in the following sentence. If the Closing shall have occurred under this Agreement, the matter shall be resolved pursuant
to the arbitration provisions contained in Section 9(i); and if the Closing shall not have occurred under this Agreement, the Indemnified
Party may bring an action against the Indemnifying Party in any court located in Los Angeles County, California.

 

    	 	15	 

     

    

 

f.            Third
Party Claims. With respect to a Third Party Claim, if after receipt of the Claim Notice the Indemnifying Party acknowledges
in writing to the Indemnified Party that the Indemnifying Party shall be obligated under the terms of its indemnity hereunder in
connection with such lawsuit or action, the Indemnifying Party shall be entitled, if it so elects at its own cost, risk and expense,
(A) to take control of the defense and investigation of such lawsuit or action, (B) to employ and engage attorneys of its own choice,
but, in any event, reasonably acceptable to the Indemnified Party, to handle and defend the same unless the named parties to such
action or proceeding (including any impleaded parties) include both the Indemnifying Party and the Indemnified Party and the Indemnified
Party has been advised in writing by counsel that there may be one or more legal defenses available to such Indemnified Party that
are different from or additional to those available to the Indemnifying Party, in which event the Indemnified Party shall be entitled,
at the Indemnifying Party’s cost, risk and expense, to separate counsel of its own choosing, and (C) to compromise or settle
such lawsuit or action, which compromise or settlement shall be made only with the written consent of the Indemnified Party, such
consent not to be unreasonably withheld.

 

If the Indemnifying Party fails
to assume the defense of such Claim within 30 calendar days after receipt of the Claim Notice, the indemnified party against which
such Claim has been asserted will (upon delivering notice to such effect to the Indemnifying Party) have the right to undertake,
at the Indemnifying Party’s cost and expense, the defense, compromise or settlement of such Claim on behalf of and for the
account and risk of the Indemnifying Party. If the Indemnified Party assumes the defense of the Claim, the Indemnified Party will
keep the Indemnifying Party reasonably informed of the progress of any such defense, compromise or settlement. The Indemnifying
Party shall be liable for any settlement of any action effected pursuant to and in accordance with this Section 7(f) and for any
final judgment (subject to any right of appeal) and the Indemnifying Party agrees to indemnify and hold harmless an Indemnified
Party from and against any Damages by reason of such settlement or judgment. If there is a dispute as to the indemnification obligations
of any party under this Section 7(f), then the parties shall proceed in the manner set forth in the following sentence. If the
Closing shall have occurred under this Agreement, the matter shall be resolved pursuant to the arbitration provisions contained
in Section 9(i); and if the Closing shall not have occurred under this Agreement, the Indemnified Party may bring an action against
the Indemnifying Party in any court located in Los Angeles County, California

 

g.           Limitation
on Indemnification. Notwithstanding anything contained herein to the contrary,

 

(i) in no event shall the aggregate
amount of the indemnifiable Losses for which Seller shall be liable pursuant to Section 7(b), or Purchaser shall be liable pursuant
to Section 7(c), exceed the fair market value on the Closing Date of the Purchaser Closing Payment; and

 

(ii) all indemnifiable Losses
shall be calculated net of the amount of any actual recoveries by an Indemnified Party under applicable insurance policies (calculated
net of any actual collection costs and reserves, expenses, deductibles or premium adjustments or retrospectively rated premiums
incurred or paid to procure such recoveries).

 

    	 	16	 

     

    

 

h.           Remedies
Cumulative. The foregoing
indemnification provisions are in addition to, and not in derogation of, any remedy at law or in equity that any Party may have
with respect to this Agreement and the transactions contemplated hereby. 

 

8.          Taxes.

 

a.           Payment of Taxes, Filing of Returns.
Seller shall remain liable for the filing of all
tax returns and reports and for the payment of all foreign, federal, state and local taxes of either Seller relating to the operation
of the business of Seller or to the Assets for any period ending on or prior to the Closing Date, and for the payment of all taxes
attributable to or relating to the consummation of the Transaction contemplated herein and shall indemnify and hold each of Apollo
and Acquisition harmless from and against all liability in connection therewith.

 

b.           Income,
Sales and Other Taxes. Seller shall bear all responsibility for income, sales, use,
value added or other similar taxes, if any, arising out of the consummation of the Transaction herein provided for and shall be
liable for the filing of all necessary tax returns and reports with respect to such taxes.

 

9.          Miscellaneous.

 

a.           Notices.
All notices, requests, demands and other communications (a “Notice”) given pursuant to this Agreement shall be in writing,
and shall be delivered by personal service, courier, facsimile transmission, electronic transmission (the last two of which must
be confirmed) or by United States first class, registered or certified mail, postage prepaid, to the following addresses:

 

 

		To:	Apollo Medical Holdings, Inc.

or Apollo Acquisition Corporation

700 North Brand Blvd., Suite 1400

Glendale, California 91203

Tel: (818) 396-8050

Fax: (818) 844-3886

Attention: Warren Hosseinion, M.D.

 

with a copy to:

 

SEC Law Firm

11693 San Vicente Boulevard

Suite 357

Los Angeles, California 90049

Tel: (310) 557-3059

Fax: (310) 388-1320

Attention: Lance Jon Kimmel, Esq.

 

    	 	17	 

     

    

  

		To:	Healarium, Inc.

239 Dawson Road

Hillsdale, NY 12529

Attention: Oded Levy

Tel: (917) 545-4046

Fax: ________________

Attention: Oded Levy

 

with a copy to:

 

Pepper Hamilton LLP

Hercules Plaza, Suite 5100 |

1313 N. Market Street

Wilmington, Delaware 19801

Attention: Ben Strauss, Esq.

 

Any
Notice, other than a Notice sent by overnight courier mail, shall be effective when received; a Notice sent by overnight courier,
shall be effective on the delivery date. Any party may from time to time change its address for further Notices hereunder by giving
notice to the other parties in the manner prescribed in this Section 9.

 

b.           Entire
Agreement. This Agreement contains the sole and entire agreement and understanding
of the parties with respect to the entire subject matter of this Agreement, and supersedes any and all prior discussions, negotiations,
commitments and understandings, whether oral or otherwise, related to the subject matter of this Agreement.

 

c.           Assignment. No
party may assign this Agreement, and any attempted or purported assignment or any delegation of any party’s duties or obligations
arising under this Agreement to any third party or entity shall be deemed to be null and void, and shall constitute a material
breach by such party of its duties and obligations under this Agreement; provided that Apollo may assign its rights to purchase
all or any portion of the Assets to any wholly-owned subsidiary presently existing or to be formed, whether such subsidiary is
established under the laws of any State or outside the United States; provided further
that Apollo shall remain responsible for its obligations set forth in this Agreement and the Transaction Documents. Subject to
the preceding sentence, this Agreement shall inure to the benefit of and be binding upon each of the parties and their respective
successors and permitted assigns. Nothing expressed or referred to in this Agreement will be construed to give any Person other
than the parties any legal or equitable right, remedy or Claim under or with respect to this Agreement or any provision of this
Agreement.

 

    	 	18	 

     

    

  

d.           Waiver
and Amendment. No provision of this Agreement may be waived unless in writing signed
by all the parties to this Agreement, and waiver of any one provision of this Agreement shall not be deemed to be a waiver of
any other provision.  This Agreement may be amended only by a written agreement executed by all of the parties to this Agreement.

 

e.           Severability. Whenever
possible each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement shall be or become prohibited or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity without invalidating the remainder of such provision or the remaining
provisions of this Agreement.

 

f.            Captions. The
various captions of this Agreement are for reference only and shall not be considered or referred to in resolving questions of
interpretation of this Agreement.

 

g.           Governing
Law. This Agreement has been made and entered into in the State of Delaware and
shall be construed in accordance with the laws of the State of Delaware without giving effect to the principles of conflicts of
law thereof.

 

h.           Costs
and Attorneys’ Fees. If any action, suit, arbitration or other proceeding
is instituted to remedy, prevent or obtain relief from a default in the performance by any party to this Agreement of its obligations
under this Agreement, the prevailing party shall recover all of such party’s attorneys’ fees incurred in each and
every such action, suit, arbitration or other proceeding, including any and all appeals or petitions therefrom.  As used
in this Section 9(h), attorneys’ fees shall be deemed to mean the full and actual costs of any legal services actually performed
in connection with the matters involved calculated on the basis of the usual fee charged by the attorney performing such services
and shall not be limited to “reasonable attorneys’ fees” as defined in any statute or rule of court.

 

i.            Dispute
Resolution.

 

Except
for specific performance and other equitable relief provided for in this Agreement, if any controversy or claim arising out of
this Agreement cannot be settled by the parties, the controversy or claim shall be submitted to and settled by arbitration as hereinafter
provided. The parties shall endeavor to agree upon a single arbitrator (the “Arbitrator”) who shall be a retired judge
provided by JAMS or equivalent organization (the “Provider”) and who shall then try all issues, whether of fact or
law, and report a finding or judgment thereon. If the parties are unable to agree upon the Arbitrator, each party shall provide
the names of five retired judges from the Provider; then each party shall choose one of the names from the list proposed by the
other, and from those two names the Arbitrator shall be selected by the flip of a coin. Prior to commencement of the arbitration
proceedings, the Arbitrator shall make a full disclosure to the parties of any prior engagement by any of the parties, or their
attorneys or law firms. Any such prior engagement shall be grounds for disqualification of the Arbitrator, and upon any such disqualification
a substitute Arbitrator shall be selected as provided herein. The arbitration proceedings shall be governed by the following:

 

    	 	19	 

     

    

  

  i.           all hearings and other proceedings shall be in Los Angeles County, California unless the parties shall mutually agree in writing to an alternative location;

 

ii.          the
Arbitrator shall follow and apply Delaware law;

 

  iii.         the California Rules of Evidence shall apply to all proceedings;

 

  iv.        discovery shall be limited to two depositions for each party and document production as allowed at the discretion of the Arbitrator within the rules of Section 1283.05 of the California Code of Civil Procedure;

 

  v.         the time for rendering a decision after hearing shall be in accordance with the published practices of the Provider;

 

vi.        provisional
remedies shall be available to the parties to the arbitration in accordance with Section 1281.8 of the California Code of Civil
Procedure;

 

vii       the
parties to the proceedings shall initially bear the arbitration fees equally; provided, however, the prevailing party
shall be entitled to recover its contribution for such fees as an item of recoverable costs in addition to all other costs; and

 

viii.      the prevailing party
may bring an action to confirm the arbitration award in any court located in Los Angeles County, California.

 

j.            Rights
Cumulative. No right granted to the parties under this Agreement on default or breach is
intended to be in full or complete satisfaction of any damages arising out of such default or breach, and each and every right
under this Agreement, or under any other document or instrument delivered hereunder, or allowed by law or equity, shall be cumulative
and may be exercised from time to time.

 

k.          Judicial
Interpretation. Should any provision of this Agreement require judicial interpretation,
it is agreed that a court interpreting or construing the same shall not apply a presumption that the terms hereof shall be more
strictly construed against any person by reason of the rule of construction that a document is to be construed more strictly against
the person who itself or through its agent prepared the same, it being agreed that all parties have participated in the preparation
of this Agreement.

 

    	 	20	 

     

    

 

l.            Force
Majeure. If any party to this Agreement is delayed in the performance of any of
its obligations under this Agreement or is prevented from performing any such obligations due to causes or events beyond its control,
including, without limitation, acts of God, fire, flood, war, terrorism, earthquake, strike or other labor problem, injunction
or other legal restraint, present or future law, governmental order, rule or regulation, then such delay or nonperformance shall
be excused and the time for performance thereof shall be extended to include the period of such delay or nonperformance.

 

m.           Counterparts. This
Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together
shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the parties have executed
this Asset Purchase Agreement as of the date first set forth above.

 

	APOLLO MEDICAL HOLDINGS, INC.	 
	 	 
	/s/ Warren Hosseinion	 
	By: Warren Hosseinion, M.D.	 
	Title: Chief Executive Officer	 
	 	 
	APOLLO CARE CONNECT, INC.	 
	 	 
	/s/ Gary Augusta	 
	By: Gary Augusta	 
	Title: Chief Executive Officer	 

 

	HEALARIUM, INC.	 
	 	 
	/s/ Oded Levy	 
	By: Oded Levy	 
	Title: President	 

 

    	 	21	 

     

    

 

Schedule “I”

 

Assets

 

For purposes of this Agreement, the term:

 

1.      “Assets” shall mean (i) Patent Applications, (ii) Intellectual Property, and (iii) any other assets of Seller currently
used by Seller in connection with the Intellectual Property and not specifically listed below as Excluded Assets.

 

2.      “Patent Applications” shall mean:

 

·          
U.S.
Provisional Patent Application No. 61/094986 and No. 61/138,177 filed Sept 8th, 2008 and Dec 17th, 2008 respectively.

 

·          
Israel
patent application reference 6589 including related documents provided to seller during diligence:

 

·          
6589
as FILED, Specification, April 13th 2015 and May 20th 2015 patent amendment

 

3.      “Intellectual
Property” shall mean:

 

		·	The source code underlying the platform which was developed by Seller under that certain Verizon Master Service Agreement (
MA-003313-2011) made as of Jan 13, 2002 and Jan 5, 2002 by and between Verizon and Healarium ()the “Verizon Agreement”),
and all Seller’s rights related thereto

 

		·	All trademarks, trade names, service marks and copyrights, whether registered or not, used in Seller’s business as presently
conducted, including without limitation:

 

·          
Healthies
trademark Reg. No. 4100054 registered on 02/14/2012.

 

·          
Healarium
LOGO Reg No 4236649 registered on 11/06/2012.

 

		·	all proprietary knowledge, trade secrets, confidential information, computer software and licenses, formulae, source code,
source documentation, training material, installation documentation, designs
and drawings, quality control data, processes (whether secret or not), methods, inventions and other similar know-how or rights
relating to or arising out of the Intellectual Property, including without limitation:

 

    	 	22	 

     

    

 

1.    
Web server source

2.     Android & iOS
client’s sources;

3.     BI (SSRS - reporting,
SSIS - integration (etl), SSAS - analysis (cubes)) sources;

4.    
BI databases: STG & DWH

5.    
Demo database version 3.0.1

6.    
Development database version 3.2.2

7.    
Drupal sources

8.     Configuration documentations,

9.     Test Cases,

10.  Environments Access

11.  Issue Tracking
system access

12. Verizon Master Services
Agreement to include:

- Personal Health Assistant
– Web Client

- Personal Health Assistant
– Smartphone Client

- Supervision Assistant

- Executive Assistant

- Admin

 

		·	Records (as defined in Section 3(b)(x) herein);

 

		·	The names “Healarium”, and any similar or derivative name(s) or variations thereof;

 

		·	All web sites and URLs used in Seller’s business as present conducted, including without limitation:

 

·         
www.healarium.com

 

		·	All Seller’s technology documentation related to Intellectual
Property including, but not limited to:

 

		·	Healarium Reference Guide 2.0 through 3.2

		·	Healarium Open Source Components 3.0

		·	Healarium PHA Administrative Guide 3.2

 

4.      “Licensed
Technology”, means:

 

		·	All third-party licensed software (“Licensed Software”)
used in Seller’s business as presently conducted, including without limitation:

·         
Microsoft
_SQL Server

·         
Panorama

·         
Microsoft
Excel

·         
Oracle

 

    	 	23	 

     

    

 

·         
Python

·         
Django

·         
Linux

·         
IIS

·         
Apache

·         
Microsoft
OLAP Cube

·         
Web
Client Technology – HTML5, CSS, JavaScript

·         
Other
related 3rd party development software used in delivery of Healarium operating platform including all components within
Verizon Master Services Agreement

 

5.      “Contracts” means:

 

		·	all license, sales, service and similar agreements to which Seller is presently a party, including without limitation:

 

·         
Verizon
Master Service Agreement ( MA-003313-2011) made as of Jan 13, 2002 and Jan 5, 2002 by and between Verizon and Healarium, which
agreement expired in January 2015 and was not renewed;

 

·         
Care
Here Customer Agreement between Care Here and Healarium; including

 

		·	June 23rd, 2011 Signed Care Here Agreement

 

		·	First Amendment to Care Here

 

		·	Any other Care Here agreements

 

		·	All confidentiality, non-disclosure, mutual non-disclosure or similar agreements to which Seller is a party, including without
limitation:

 

		·	Nondisclosure Agreements from:

 

		§	Clemson, Child Health Corp of America, UAB, ASCOM, Care Here, Mayo Clinic, MSK, Lumeris, Henry Schein

 

6.      All
other operational assets other than Excluded Assets. “Excluded Assets” means the following assets of Seller:

 

		·	The Mayo Clinic Research Shows Cardiac Rehab Patient Who Use Smartphone App Recover Better

 

    	 	24	 

     

    

 

		·	The Application of Self-Monitoring of Cardiovascular Risks, to the extent that such asset has been funded by the BIRD Foundation;

 

		·	The shares of Healarium Israel Ltd.; and

 

		·	Other non-operational assets of Seller or Healarium Israel Ltd.

 

    	 	25	 

     

    

 

Exhibit “A”

 

FORM OF

PATENT APPLICATION ASSIGNMENT

 

Healarium, Inc. (“Assignor”)
is owner of Method and System for Analyzing Health Related Data of Patients (the “Invention”), as described in the
U.S. Patent Application with U.S. Patent and Trademark Office (“USPTO”) Serial Number 61/094986, filed on September
8, 2008 (the “Patent Application”). Pursuant to that certain Asset Purchase Agreement dated January 12, 2016 by and
among Apollo Medical Holdings, Inc., a Delaware corporation, Apollo Care Connect, Inc., a Delaware corporation and a wholly-owned
subsidiary of Apollo (“Assignee”), and Assignor, Assignee desires to acquire all rights in and to the Patent Application
and the patent that may be issued in connection therewith (the “Patent”), and all reexaminations, reissues or extensions
that may be granted in connection therewith.

 

Therefore, for good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, Assignor hereby assigns to Assignee and its successors and assigns,
all of Assignor’s right, title, and interest in and to the Invention and Patent Application (as well as such rights in any
divisions, continuations in whole or part or substitute applications) for the entire term of the issued Patent and all reexaminations,
reissues or extensions that may be granted in connection therewith, and for the entire respective terms of any and all foreign
patents that may issue from foreign applications (as well as divisions, continuations in whole or part or substitute applications)
filed claiming the benefit of the Patent Application.

 

Assignor authorizes the USPTO and requests
the Commissioner of Patents of the United States to record this assignment of all right, title and interest in the Patent to Assignee,
and to issue any Patents resulting from the Patent Application to Assignee. This right, title and interest is to be held and enjoyed
by Assignee and its successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this
assignment not been made.

 

Assignor further agrees to: (a) cooperate
fully with Assignee in the prosecution of the Patent Application and foreign counterparts; (b) execute, verify, acknowledge and
deliver all such further papers, including patent applications and instruments of transfer as Assignee may reasonably request;
and (c) perform such other acts as Assignee lawfully may request to obtain or maintain the Patent for the invention in any and
all countries.

 

	Date: January 12, 2016	HEALARIUM, INC. (“Assignor”)

 

	 	By 	/s/ Oded Levy
	 	 	Oded Levy
	 	Title: 	President

 

    	 	26	 

     

    

 

Exhibit “B”

 

GENERAL CONVEYANCE, BILL OF SALE AND
ASSIGNMENT AGREEMENT

 

This GENERAL CONVEYANCE, BILL OF SALE AND
ASSIGNMENT AGREEMENT dated as of January 12, 2016 is executed and delivered by Healarium, Inc. a Delaware corporation (“Seller”)
to Apollo Medical Holdings, Inc., a Delaware corporation (“Apollo”) and Apollo Care Connect, Inc., a Delaware corporation
(individually, “Acquisition” and collectively with Apollo, “Purchaser”).

 

WITNESSETH:

 

WHEREAS, Seller and Purchaser are parties
to that certain Asset Purchase Agreement dated as of January 12, 2016 (the “Asset Purchase Agreement”), pursuant to
which, among other things, Seller has agreed to sell and transfer, and Purchaser has agreed to purchase and accept, the Assets
(as defined in the Asset Purchase Agreement; and

 

WHEREAS, it is a condition to the Closing
(as defined in the Asset Purchase Agreement) that Sellers enters into this Bill of Sale to sell and transfer to Purchaser the Assets;

 

WHEREAS, pursuant to the Asset Purchase
Agreement, the Seller has agreed to sell, transfer, convey, assign and deliver to Purchaser the Assets.

 

NOW, THEREFORE, in consideration of the
payment by the Parties to each other of the Purchase Price (as defined in the Asset Purchase Agreement) and in further consideration
of the mutual covenants and agreements contained in the Asset Purchase Agreement, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Seller hereby agrees as follows:

 

1.          Seller
hereby sells, transfers, conveys, assigns and delivers to Purchaser and their respective successors and assigns, all right, title
and interest in and to the Assets, free and clear of any and all liens, claims and Encumbrances (as defined in the Asset Purchase
Agreement), to have and to hold, all and singular, for Purchaser’s and its successors’ and assigns’ own use forever.

 

2.          Seller hereby agree to execute and deliver
on and after the date hereof such other instruments or documents and to take such additional actions as may be reasonably requested
by the other in order to effect or complete the transfers contemplated hereby. Each party hereby agrees on demand to make, execute,
acknowledge and deliver any and all further documents and instruments, and to do and cause to be done all such further acts, reasonably
requested by the other party to evidence and/or in any manner to perfect the transfers and assignment to Purchaser of the Assets
contemplated hereby.

 

    	 	27	 

     

    

 

3.           This Bill of Sale is intended to evidence the consummation
of the sale and transfer by the Seller to the Purchaser of the Assets, all as contemplated by the Asset Purchase Agreement. The
Seller, by its execution of this Bill of Sale, and the Purchaser, by their acceptance of this Bill of Sale, each hereby acknowledges
and agrees that the remedies of any party under the Asset Purchase Agreement shall not be deemed to be enlarged, modified or altered
in any way by this Bill of Sale. Any inconsistencies or ambiguities between this Bill of Sale and the Asset Purchase Agreement
shall be resolved in favor of the Asset Purchase Agreement.

 

4.           This Bill of Sale shall inure to the
benefit of and is binding upon the respective successors and assigns of the Seller and Purchaser.

 

5.           This Bill of Sale shall be governed
by and construed in accordance with the laws of the State of Delaware, without giving effect to conflict of law principles thereof.

 

IN WITNESS WHEREOF, the parties have caused
this Bill of Sale to be executed and delivered by their duly authorized representatives effective as of the date first written
above.

 

	 	HEALARIUM, INC., as Seller
	 	 
	 	By:	/s/ Oded Levy
	 	 	Oded Levy
	 	Title:	President

 

	AGREED AND ACCEPTED:	 
	 	 
	APOLLO MEDICAL HOLDINGS, INC., as Purchaser	 
	 	 	 
	By: 	/s/ Warren Hosseinion	 
	 	Warren Hosseinion	 
	Title:	Chief Executive Officer	 
	 	 	 
	APOLLO CARE CONNECT, INC., as Buyer	 
	 	 	 
	By:	/s/ Gary Augusta	 
	 	Gary Augusta	 
	Title: 	Chief Executive Officer	 

 

    	 	28	 

     

    

 

Exhibit “C”

 

NON-DISCLOSURE AGREEMENT

 

    	 	29

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]